U.S. patent application number 09/988127 was filed with the patent office on 2002-08-22 for methods of controlling proliferation and differentiation of stem and progenitor cells.
Invention is credited to Fibach, Eitan, Peled, Tony, Treves, Avi.
Application Number | 20020114789 09/988127 |
Document ID | / |
Family ID | 23839684 |
Filed Date | 2002-08-22 |
United States Patent
Application |
20020114789 |
Kind Code |
A1 |
Peled, Tony ; et
al. |
August 22, 2002 |
Methods of controlling proliferation and differentiation of stem
and progenitor cells
Abstract
A method of expanding a population of cells, while at the same
time inhibiting differentiation of the cells, the method includes
the step of providing the cells with conditions for cell
proliferation and, at the same time, for reducing a capacity of the
cells in utilizing copper. The method can be executed both in-vivo
and ex-vivo. A method of inducing differentiation in a population
of cells, the method includes the step of providing the cells with
a transition metal chelator which binds copper and which is
effective in inducing cell differentiation.
Inventors: |
Peled, Tony; (Mevaseret
Zion, IL) ; Fibach, Eitan; (Mevaseret Zion, IL)
; Treves, Avi; (Mevaseret Zion, IL) |
Correspondence
Address: |
G. E. EHRLICH (1995) LTD.
c/o ANTHONY CASTORINA
SUITE 207
2001 JEFFERSON DAVIS HIGHWAY
ARLINGTON
VA
22202
US
|
Family ID: |
23839684 |
Appl. No.: |
09/988127 |
Filed: |
November 19, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09988127 |
Nov 19, 2001 |
|
|
|
09463320 |
Jan 22, 2000 |
|
|
|
09463320 |
Jan 22, 2000 |
|
|
|
PCT/IL99/00444 |
Aug 17, 1999 |
|
|
|
Current U.S.
Class: |
424/93.21 ;
424/85.1 |
Current CPC
Class: |
A61K 35/28 20130101 |
Class at
Publication: |
424/93.21 ;
424/85.1 |
International
Class: |
A61K 048/00; A61K
038/19 |
Foreign Application Data
Date |
Code |
Application Number |
Feb 8, 1999 |
US |
PCT/US99/02664 |
Claims
What is claimed is:
1. A method of hematopoietic cells transplantation comprising the
steps of: (a) obtaining hematopoietic cells to be transplanted from
a donor; (b) providing said cells ex-vivo with conditions for cell
proliferation and, at the same time, for reducing a capacity of
said cells in utilizing cooper, thereby expanding a population of
said cells, while at the same time, inhibiting differentiation of
said cells; and (c) transplanting said cells to a patient.
2. The method of claim 1, wherein said donor and said patient are a
single individual.
3. The method of claim 1, wherein obtaining said hematopoetic cells
is from a source selected from the group consisting of peripheral
blood, bone marrow, neonatal umbilical cord blood and embryonic
stem cells.
4. The method of claim 3, wherein obtaining said hematopoietic
cells further includes enriching said cells for stem cells.
5. The method of claim 3, wherein obtaining said hematopoietic
cells further includes enriching said cells for progenitor
cells.
6. The method of claim 1, wherein reducing said capacity of the
cells in utilizing copper is effected by a transition metal
chelator having an affinity to copper.
7. The method of claim 6, wherein said transition metal chelator is
selected from the group consisting of polyamine chelating agents,
ethylendiamine, diethylenetriamine, triethylenetetramine,
triethylenediamine, tetraethylenepentamine, aminoethylethanolamine,
aminoethylpiperazine, pentaethylenehexamine, t
triethylenetetramine-hydro- chloride,
tetraethylenepentamine-hydrochloride, pentaethylenehexamine-hydr-
ochloride, tetraethylpentamine, captopril, penicilamine,
N,N'-bis(3-aminopropyl)-1,3-propanediamine, N,N,Bis (2 animoethyl)
1,3 propane diamine, 1,7-dioxa-4,10-diazacyclododecane,
1,4,8,11-tetraaza cyclotetradecane-5,7-dione,
1,4,7-triazacyclononane trihydrochloride,
1-oxa-4,7,10-triazacyclododecane, 1,4,8,12-tetraaza
cyclopentadecane, 1,4,7,10-tetraaza cyclododecane.
8. The method of claim 1, wherein providing the cells with said
conditions for cell proliferation include providing the cells with
nutrients and with cytokines.
9. The method of claim 8, wherein said cytokines are early acting
cytokines.
10. The method of claim 9, wherein said early acting cytokines are
selected from the group consisting of stem cell factor, FLT3
ligand, interleukin-6, thrombopoietin and interleukin-3.
11. The method of claim 8, wherein said cytokines are late acting
cytokines.
12. The method of claim 11, wherein said late acting cytokines are
selected from the group consisting of granulocyte colony
stimulating factor, granulocyte/macrophage colony stimulating
factor and erythropoietin.
13. The method of claim 1, wherein said cells are derived from a
source selected from the group consisting of bone marrow,
peripheral blood and neonatal umbilical cord blood.
14. The method of claim 1, wherein said cells are enriched for
hematopoietic CD.sub.34+ cells.
15. The method of claim 1, wherein said cells are selected from the
group consisting of non-differentiated stem cells and committed
progenitor cells.
16. A method of genetically modifying stem cells with an exogene
comprising the steps of: (a) obtaining stem cells to be genetically
modified; (b) providing said cells ex-vivo with conditions for cell
proliferation and, at the same time, for reducing a capacity of
said cells in utilizing cooper, thereby expanding a population of
said cells, while at the same time, inhibiting differentiation of
said cells; and (c) genetically modifying said cells with the
exogene.
17. The method of claim 16, wherein genetically modifying is
effected by a vector including the exogene.
18. The method of claim 16, wherein reducing said capacity of the
cells in utilizing copper is effected by a transition metal
chelator having an affinity to copper.
19. The method of claim 18, wherein said transition metal chelator
is selected from the group consisting of polyamine chelating
agents, ethylendiamine, diethylenetriamine, triethylenetetramine,
triethylenediamine, tetraethylenepentamine, aminoethylethanolamine,
aminoethylpiperazine, pentaethylenehexamine,
tethylenetetramine-hydrochlo- ride,
tetraethylenepentamine-hydrochloride,
pentaethylenehexamine-hydrochl- oride, tetraethylpentamine,
captopril, penicilamine,
N,N'-bis(3-aminopropyl)-1,3-propanediamine, N,NBis (2 animoethyl)
1,3 propane diamine, 1,7-dioxa-4,10-diazacyclododecane,
1,4,8,11-tetraaza cyclotetradecane-5,7-dione,
1,4,7-triazacyclononane trihydrochloride,
1-oxa-4,7,10-triazacyclododecane, 1,4,8,12-tetraaza
cyclopentadecane, 1,4,7,10-tetraaza cyclododecane.
20. The method of claim 16, wherein providing the cells with said
conditions for cell proliferation include providing the cells with
nutrients and with cytokines.
21. The method of claim 20, wherein said cytokines are early acting
cytokines.
22. The method of claim 21, wherein said early acting cytokines are
selected from the group consisting of stem cell factor, FLT3
ligand, interleukin-6, thrombopoietin and interleukin-3.
23. The method of claim 20, wherein said cytokines are late acting
cytokines.
24. The method of claim 23, wherein said late acting cytokines are
selected from the group consisting of granulocyte colony
stimulating factor, granulocyte/macrophage colony stimulating
factor and erythropoietin.
25. The method of claim 16, wherein said cells are derived from a
source selected from the group consisting of bone marrow,
peripheral blood and neonatal umbilical cord blood.
26. A method of adoptive immunotherapy comprising the steps of: (a)
obtaining progenitor hematopoietic cells from a patient; (b)
providing said cells ex-vivo with conditions for cell proliferation
and, at the same time, for reducing a capacity of said cells in
utilizing cooper, thereby expanding a population of said cells,
while at the same time, inhibiting differentiation of said cells;
and (c) transplanting said cells to the patient.
27. The method of claim 26, wherein reducing said capacity of the
cells in utilizing copper is effected by a transition metal
chelator having an affinity to copper.
28. The method of claim 27, wherein said transition metal chelator
is selected from the group consisting of polyamine chelating
agents, ethylendiamine, diethylenetriamine, triethylenetetramine,
triethylenediamine, tetraethylenepentamine, aminoethylethanolamine,
aminoethylpiperazine, pentaethylenehexamine,
triethylenetetramine-hydroch- loride,
tetraethylenepentamine-hydrochloride, pentaethylenehexamine-hydroc-
hloride, tetraethylpentamine, captopril, penicilamime,
N,N'-bis(3-aminopropyli 1,3-propanediamine, N,N,Bis (2 animoethyl)
1,3 propane diamine, 1,7-dioxa-4,10-diazacyclododecane,
1,4,8,11-tetraaza cyclotetradecane-5,7-dione,
1,4,7-triazacyclononane trihydrochloride,
1-oxa-4,7,10-triazacyclododecane, 1,4,8,12-tetraaza
cyclopentadecane, 1,4,7,10-tetraaza cyclododecane.
29. The method of claim 26, wherein providing the cells with said
conditions for cell proliferation include providing the cells with
nutrients and with cytokines.
30. The method of claim 29, wherein said cytokines are early acting
cytokines.
31. The method of claim 30, wherein said early acting cytokines are
selected from the group consisting of stem cell factor, FLT3
ligand, interleukin-6, thrombopoietin and interleukin-3.
32. The method of claim 29, wherein said cytokines are late acting
cytokines.
33. The method of claim 32, wherein said late acting cytokines are
selected from the group consisting of granulocyte colony
stimulating factor, granulocyte/macrophage colony stimulating
factor and erythropoietin.
34. The method of claim 26, wherein said cells are derived from a
source selected from the group consisting of bone marrow,
peripheral blood and neonatal umbilical cord blood.
35. The method of claim 26, wherein said cells are enriched for
hematopoietic CD.sub.34+ cells.
36. The method of claim 26, wherein said cells are selected from
the group consisting of non-differentiated stem cells and committed
progenitor cells.
Description
[0001] This is a continuation of PCT/IL99/00444, filed Aug. 17,
1999, which claims priority from U.S. patent application Ser. No.
09/161,659, filed Sep. 29, 1998, which is a continuation in part of
U.S. patent application Ser. No. 09/130,367, filed Aug. 7, 1998,
which is a continuation in part of U.S. patent application Ser. No.
09/024,195, filed Feb. 17, 1998. In addition, PCT/IL99/00444 claims
priority from PCT/US99/02664, filed Feb. 8, 1999, which claims
priority from U.S. patent application Ser. Nos. 09/024,195 and
09/30,367.
FIELD AND BACKGROUND OF THE INVENTION
[0002] The present invention relates to methods of controlling
proliferation and differentiation of stem and progenitor cells. In
one aspect, the present invention relates to a method of imposing
proliferation yet restricting differentiation of stem and
progenitor cells by treating the cells with chelators of
transitional metals, resulting in reduction if transitional metals
availability. In another aspect, the present invention relates to a
method of inducing differentiation of cells by treating the cells
with chelators of transitional metals, resulting in increase in
transitional metals availability to the cells. In still another
aspect, the present invention relates to assays for determining
whether a specific chelator of transitional metals will restrict or
induce differentiation.
[0003] Cell Differentiation and Proliferation
[0004] Normal production of blood cells (hematopoiesis) and of
other cell types involves the processes of proliferation and
differentiation which are tightly coupled. In most hematopoietic
cells following division the daughter cells undergo a series of
progressive changes which eventually culminate in fully
differentiated (mature), functional blood cells, which in most part
are devoid of proliferative potential. Thus, the process of
differentiation limits, and eventually halts cell division. Only in
a small minority of the hematopoietic cells, known as stem cells,
cell division may result in progeny which are similar or identical
to their parental cells. This type of cell division, known as
self-renewal, is an inherent property of stem cells and helps to
maintain a small pool of stem cells in their most undifferentiated
state. Some stem cells lose their self-renewal capacity and
following cell division differentiate into various types of lineage
committed progenitors which finally give rise to mature cells.
While the latter provide the functional capacity of the blood cell
system, the stem cells are responsible for the maintaining of
hematopoiesis throughout life despite a continuous loss of the more
differentiated cells through apoptosis (programmed cell death)
and/or active removal of aging mature cells by the
reticuloendothelial system. It will be appreciated that in one way
or another these processes characterize all other cell lineages of
multicellular organisms, because replenishment of dead cells occurs
during the life cycle of such organisms Normal hematopoiesis is
coordinated by a variety of regulators which include glycoproteins
such as the colony stimulating factors (CSF), as well as small
molecules such as the retinoids. They regulate the survival (e.g.,
by inhibiting apoptosis), proliferation and differentiation of
progenitor and precursor cells and the activation state of mature
cells.
[0005] In acute leukemia, for example, there is a block in cell
differentiation. As a results, the leukemic cells maintain their
proliferative potential. Leukemic cells do not respond normally to
the various regulators (54). Thus, cells obtained from patients
with acute myeloid leukemia develop in culture, in response to
stimulation by colony stimulating factor (CSF), small colonies of
undifferentiated cells, as compared to large colonies of
granulocytes and macrophages, which develop following cloning
normal hematopoietic cells.
[0006] As further detailed below, expansion of the stem cell and
other defined lympho-hematopoietic cell subpopulations by ex-vivo
culturing could have important clinical applications.
[0007] A variety of protocols have been suggested and experimented
for enrichment of such populations. The main experimental
strategies employed include incubation of mononuclear cells with or
without selection of CD.sub.34.sup.+ (8); with different cocktails
of early and late growth factors (17); with or without serum (7);
in stationary cultures, rapid medium exchanged cultures (18) or
under continuous perfusion (bioreactors) (6); and with or without
established stromal cell layer(19).
[0008] Although a significant expansion of intermediate and late
progenitors was often obtained during 7-14 days ex-vivo cultures,
the magnitude of early hematopoietic
(CD.sub.34.sup..degree.CD.sub.38.sup.-) stem cells with high
proliferative potential, usually declined (6, 20-22).
[0009] Thus, these cultures do not result in true stem cell
expansion, but rather in proliferation and differentiation of the
stem cells into pre-progenitor cells, accompanied by depletion of
the primitive stem cell pool.
[0010] In order to achieve maximal ex-vivo expansion of stem cells
the following conditions should be fulfilled: (i) differentiation
should be reversibly inhibited or delayed and (ii) self-renewal
should be maximally prolonged.
[0011] Similarly, following cell expansion, it is important to have
methods to induce differentiation of the expanded cell population,
so as to covert the expanded cell population to mature functional
cells or tissue.
[0012] Role of Copper in cell differentiation:
[0013] The possible involvement of Copper in hematopoietic cell
development could be inferred from the following findings:
[0014] Clinical Symptoms in Copper Deficiency:
[0015] Copper deficiency can result from hereditary defects, such
as Menkes syndrome or Celiac disease, or from acquired conditions.
The latter is typically associated with malnourishment. It may be
caused by Copper non-supplemented total parenteral nutrition (e.g.,
following intestinal resection), by consumption of high levels of
Zinc, which interferes with Copper utilization, in underweight
and/or cow milk (poor source of Copper) fed new-borns, which may
result in severe cases in Shwanchman syndrome. Unbalanced treatment
with Copper chelators in Copper overload cases such as in Wilson's
disease may also lead to Copper deficiency.
[0016] The clinical symptoms of Copper deficiency may include
impairment of growth, brain development, bone strength and
morphology, myocardial contractility, cholesterol and glucose
metabolism, host defence (immune) mechanisms and more.
[0017] Of particular relevance to this study is the fact that
Copper deficiency is often associated with hematological
abnormalities, including anemia, neutropenia and thrombocytopenia.
All these pathological manifestations are unresponsive to iron
therapy, but are rapidly reversed following Copper supplementation
(27-28).
[0018] The mechanism by which Copper deficiency leads to
neutropenia is unknown. Among the possible causes, either alone or
in combination, are: (i) early death of progenitor cells in the
bone marrow (BM); (ii) impaired formation of neutrophils from
progenitor cells in the BM; (iii) decrease in cellular maturation
rate in the BM; (iv) impaired release of neutrophils from the BM to
the circulation; (v) enhanced elimination rate of circulating
neutrophils.
[0019] Examination of the BM of neutropenic Copper-deficient
patients demonstrates the absence of mature cells ("maturation
arrest"). It has been shown that cells derived from such BM did not
form colonies in semi-solid medium containing Copper deficient
serum, but retained the potential for normal colony growth in
Copper containing serum. These results indicate the presence of
intact progenitors in the patient's BM, and suggest that the block
in IO development occurs distal to the progenitor stage
(29-30).
[0020] The Effect of Copper in Cell Lines:
[0021] The effect of Copper was also studied in-vitro established
cell lines (31-34). One such line (HL-60) was derived from a
patient with acute promyelocytic leukemia. These cells, that have
the characteristics of myeloblasts and promyelocytes, can grow
indefinitely in culture. Upon addition of various agents, such as
retinoic acid (RA), to the culture medium, the cells undergo
differentiation, which results in cells which demonstrate some, but
not all, features of mature granulocytes.
[0022] The study of Copper status in these cells has shown that
although the cytosolic Copper content per cell was not
significantly different in RA-treated cells compared to untreated
cells, the Copper content per protein content was doubled. This is
due to the fact that RA-treated cells have about half the protein
content as compared to their untreated counterpart. Using
.sup.67Cu, it has been shown that the rate of Copper uptake was
significantly faster during the two first days of RA treatment, but
not at later times. The intracellular distribution of .sup.67Cu was
found predominantly in high molecular weight (MW) fractions
(>100 kD) and a lower MW fraction of about 20 kD, with a higher
proportion of Copper present in the high MW fractions in RA-treated
cells.
[0023] Addition of excess Copper to regular serum-supplemented
growth medium modestly increased RA-induced differentiation.
Although RA-treated HL-60 cells do not necessarily represent normal
cell development, these results point to the possibility that
neutrophilic differentiation may require Copper.
[0024] In other experiments it has been shown that HL-60 cells can
be made Copper deficient by treatment with Copper chelators, and
that following such treatment their viability and growth rate were
unaffected.
[0025] Although all these phenomena have been attributed to Copper,
it has been reported that some clinical and biological effects are
shared by Copper and other transition metals:
[0026] For example, clinical symptoms similar to those observed in
Copper-deficiency could also be observed following consumption of
high levels of Zinc (40-42), which has been known to interfere with
Copper utilization (e.g., 43).
[0027] In a study of human hepatocellular carcinoma it was found
that the concentrations of both Copper and Zinc in the tumor tissue
decreased with the degree of histological differentiation (44).
[0028] In another study it was shown that addition of Copper, Zinc
and Ferrum to primary cultures of rat hepatocytes induced cell
replication and formation of duct-like structures. The cells lining
the ducts became morphologically and biochemically characteristic
of bile duct cells (45).
[0029] Various transition metals are known to influence the
production and activities of many enzymes and transcription factors
associated with differentiation. Examples include the Cu/Zn
containing superoxide dismutase (46); the metallothioneins and
their transcription regulating factors (e.g., MTF-1) (47-49); the
70 kDa heat shock protein (hsp70) (50); the p62 protein which
associates with the ras-GTPase activating protein during
keratinocyte differentiation (51); a neutral sphingomyellnase which
is activated during induced differentiation of HL-60 cells (52);
and the bovine lens leucine aminopeptidase (53).
[0030] Oligopeptides, either natural or synthetic, can bind Copper
too. Thus, glycyl-L-histidyl-L-lysine-Cu.sup.2+ (GHL-Cu) is a
tripeptide-Copper complex that was isolated from human plasma. It
has been shown to have, in nanomolar concentrations, a variety of
biological effects both in-vitro and in-vivo: It was first
described as a growth factor for a variety of differentiated cells
(55). Subsequent data from various groups indicated that it
exhibited several properties of a potent activator of the wound
healing process. It was a potent chemotactic agent for
monocytes/macrophages and mast cells (56-57). It stimulated nerve
tissue regeneration (58) and was reported to trigger the
angiogenesis process in-vivo (59). It stimulated collagen synthesis
in several fibroblast strains (60). It accelerated wound closure
when injected into superficial wounds in animals (61-62) and
accumulation of collagen and dermatan sulfate proteoglycans (63).
It also exerted metabolic effects, such as inhibition of lipid
peroxidation by feritin (64). GHL-metal ions combinations were
shown to promote monolayer formation and cellular adhesiveness in
tumorigenic hepatoma (HTC.sub.4) cells in culture, resulting in
marked enhancement of cell survival and growth under basal (growth
limiting) conditions (65). The mode of action of GHL is unknown. It
has been reported that GHL forms chelates with Copper and iron in
human plasma and in buffered solution at physiological pH.
[0031] While reducing the present invention to practice, it was
found that a series of chemical agents that bind (chelate)
transition metals, Copper in particular, can inhibit (delay) the
process of differentiation of stem cells as well as intermediate
and late progenitor cells and thereby stimulate and prolong the
phase of active cell proliferation and expansion ex-vivo. This
newly discovered effect of Copper and other transition metals
depletion (either partial or complete depletion) was used for
maximizing the ex-vivo expansion of various types of cells as
further detailed hereinunder. However, it was also found, while
reducing the present invention to practice, that a series of other
transition metal chelators, Copper chelators in particular, can
induce the process of differentiation in cells, e.g., both normal
and leukemic hematopoietic cells ex-vivo.
SUMMARY OF THE INVENTION
[0032] It is one object of the present invention to provide a
method of expanding a population of cells, while at the same time
inhibiting differentiation of the cells.
[0033] It is another object of the present invention to provide a
method of hematopoietic cells transplantation.
[0034] It is still another object of the present invention to
provide a method of genetically modifying stem cells with an
exogene.
[0035] It is yet another object of the present invention to provide
a method of adoptive immunotherapy.
[0036] It is an additional object of the present invention to
provide a method of mobilization of bone marrow stem cells into the
peripheral blood of a donor for harvesting the cells.
[0037] It is yet an additional object of the present invention to
provide a method of decelerating maturation/differentiation of
erythroid precursor cells for the treatment of
.beta.-hemoglobinopathic patients.
[0038] It is still an additional object of the present invention to
provide a method of preservation of stem cells.
[0039] It is a further object of the present invention to provide
stem cell collection bags.
[0040] It is still a further object of the present invention to
provide assays of determining whether a transition metal chelator
which binds copper causes inhibition or induction of
differentiation.
[0041] It is yet a further object of the present invention to
provide a method of inducing differentiation in a population of
cells
[0042] It is another object of the present invention to provide a
method of inducing terminal differentiation in acute leukemic
cells.
[0043] It is still another object of the present invention to
provide a method of induction of differentiation of non-leukemic
hematopoietic progenitor cells.
[0044] It is still another object of the present invention to
provide a method of ex-vivo differentiation of normal stem cells
into lineage committed progenitor cells.
[0045] It is an additional object of the present invention to
provide a method of ex-vivo differentiation of stem cells into
dendritic cell committed progenitors.
[0046] It is still an additional object of the present invention to
provide a pharmaceutical composition for inducing differentiation
in a population of cells.
[0047] Thus, according to one aspect of the present invention there
is provided a method of expanding a population of cells, while at
the same time inhibiting differentiation of the cells, the method
comprising the step of providing the cells with conditions for cell
proliferation and, at the same time, for reducing a capacity of the
cells in utilizing copper.
[0048] According to further features in preferred embodiments of
the invention described below, the cells are in-vivo, where th
conditions for cell proliferation are naturally provided, whereas
reducing the capacity of the cells in utilizing transition metals
is effected by administering a transition metal chelator which
binds copper.
[0049] According to still further features in the described
preferred embodiments reducing the capacity of the cells in
utilizing copper is further effected by administering Zinc.
[0050] According to still further features in the described
preferred embodiments the cells are in-vivo, where the conditions
for cell proliferation are naturally provided, whereas reducing the
capacity of the cells in utilizing copper is effected by
administering Zinc.
[0051] According to still further features in the described
preferred embodiments reducing the capacity of the cells in
utilizing copper is further effected by administering a transition
metal chelator which binds copper.
[0052] According to still further features in the described
preferred embodiments reducing the capacity of the cells in
utilizing copper is effected by a transition metal chelator that
binds copper.
[0053] According to still further features in the described
preferred embodiments the transition metal chelator is selected
from the group consisting of polyamine chelating agents,
ethylendiamine, diethylenetriamine, triethylenetetramine,
triethylenediamine, tetraethylenepentamine, aminoethylethanolamine,
aminoethylpiperazine, pentaethylenehexamine,
triethylenetetramine-hydrochloride,
tetraethylenepentamine-hydrochloride,
pentaethylenehexamine-hydrochloride- , tetraethylpentamine,
captopril, penicilamine, N,N'-bis(3-aminopropyl)-1,-
3-propanediamine, N,N,Bis (2 animoethyl) 1,3 propane diamine,
1,7-dioxa-4,10-diazacyclododecane, 1,4,8,11-tetraaza
cyclotetradecane-5,7-dione, 1,4,7-triazacyclononane
trihydrochloride, 1-oxa-4,7,10-triazacyclododecane,
1,4,8,12-tetraaza cyclopentadecane, 1,4,7,10-tetraaza
cyclododecane.
[0054] According to still further features in the described
preferred embodiments the cells are ex-vivo.
[0055] According to still further features in the described
preferred embodiments providing the cells with the conditions for
cell proliferation include providing the cells with nutrients and
with cytokines.
[0056] According to still further feats in the described preferred
embodiments the cytokines are early acting cytokines.
[0057] According to still further features in the described
preferred embodiments the early acting cytokines are selected from
the group consisting of stem cell factor, FLT3 ligand,
interleukin-6, thrombopoietin and interleukin-3.
[0058] According to still further-features in the described
preferred embodiments the cytokines are late acting cytokines.
[0059] According to still further features in the described
preferred embodiments the late acting cytokines are selected from
the group consisting of granulocyte colony stimulating factor,
granulocyte/macrophage colony stimulating factor and
erythropoietin.
[0060] According to still further features in the described
preferred embodiments the cells are selected from the group
consisting of hematopoietic cells, neural cells and oligodendrocyte
cells, skin cells, hepatic cells, embryonic stem cells, plant
cells, muscle cells, bone cells, mesenchymal cells, pancreatic
cells, chondrocytes and stroma cells.
[0061] According to still further features in the described
preferred embodiments the cells are derived from a source selected
from the group consisting of bone marrow, peripheral blood and
neonatal umbilical cord blood.
[0062] According to still further features in the described
preferred embodiments the cells are enriched for hematopoietic
CD.sub.3+ cells.
[0063] According to still further features in the described
preferred embodiments the cells are selected from the group
consisting of non-differentiated stem cells and committed
progenitor cells.
[0064] According to another aspect of the present invention there
is provided a method of hematopoietic cells transplantation
comprising the steps of (a) obtaining hematopoietic cells to be
transplanted from a donor; (b) providing the cells ex-vivo with
conditions for cell proliferation and, at the same time, for
reducing a capacity of the cells in utilizing cooper, thereby
expanding a population of the cells, while at the same time,
inhibiting differentiation of the cells; and (c) transplanting the
cells to a patient.
[0065] According to further features in preferred embodiments of
the invention described below, the donor and the patient are a
single individual.
[0066] According to still further features in the described
preferred embodiments obtaining the hematopoietic cells is from a
source selected from the group consisting of peripheral blood, bone
marrow, neonatal umbilical cord blood and embryonic stem cells.
[0067] According to still further features in the described
preferred embodiments obtaining the hematopoietic cells further
includes enriching the cells for stem cells.
[0068] According to still fewer features in the described preferred
embodiments obtaining the hematopoietic cells further includes
enriching the cells for progenitor cells.
[0069] According to yet another aspect of the present invention
there is provided a method of genetically modifying stem cells with
an exogene comprising the steps of (a) obtaining stem cells to be
genetically modified; (b) providing the cells ex-vivo with
conditions for cell proliferation and, at the same time, for
reducing a capacity of the cells in utilizing cooper, thereby
expanding a population of the cells, while at the same time,
inhibiting differentiation of the cells; and (c) genetically
modifying the cells with the exogene. Preferably, genetically
modifying is effected by a vector including the exogene.
[0070] According to still another aspect of the present invention
there is provided a method of adoptive immunotherapy comprising the
steps of (a) obtaining progenitor hematopoietic cells from a
patient; (b) providing the cells ex-vivo with conditions for cell
proliferation and, at the same time, for reducing a capacity of the
cells in utilizing cooper, thereby expanding a population of the
cells, while at the same time, inhibiting differentiation of the
cells; and (c) transplanting the cells to the patient.
[0071] According to an additional aspect of the present invention
there is provided a method of mobilization of bone marrow stem
cells into the peripheral blood of a donor for harvesting the cells
comprising the step of (a) administering to the donor an agent for
reducing a capacity of the cells in utilizing cooper, thereby
expanding a population of stem cells, while at the same time,
inhibiting differentiation of the stem cells; and (b) harvesting
the cells by leukapheresis.
[0072] According to further features in preferred embodiments of
the invention described below, the method further comprising the
step of administering the donor a cytokine.
[0073] According to still further features in the described
preferred embodiments the method further comprising the step of
administering the donor a cytokine.
[0074] According to still further features in the described
preferred embodiments the cytokine is selected from the group
consisting of stem cell factor, FLT3 ligand, interleukin-6,
thrombopoietin, interleukin-3, granulocyte colony stimulating
factor, granulocyte/macrophage colony stimulating factor and
erythropoietin.
[0075] According to yet an additional aspect of the present
invention there is provided a method of decelerating
maturation/differentiation of erythroid precursor cells for the
treatment of .beta.-hemoglobinopathic patients comprising the step
of administering to the patient an agent for reducing a capacity of
the cells in utilizing cooper, thereby expanding a population of
stem cells, while at the same time, inhibiting differentiation of
the stem cells, such that upon natural removal of the agent from
the body, the stem cells undergo accelerated maturation resulting
in elevated production of fetal hemoglobin.
[0076] According to still an additional aspect of the present
invention there is provided a therapeutical ex-vivo cultured cell
preparation comprising ex-vivo cells propagated in the presence of
an agent, the agent reducing a capacity of the cells in utilizing
cooper, thereby expanding a population of the cells, while at the
same time, inhibiting differentiation of the cells.
[0077] According to still further features in the described
preferred embodiments the agent is selected from the group
consisting of a transition metal chelator and Zinc.
[0078] According to a further aspect of the present invention there
is provided a method of preservation of stem cells comprising die
step of handling the stem cell in at least one of the steps
selected from the group consisting of harvest, isolation and
storage, in a presence of a transition metal chelator which binds
copper and/or Zinc.
[0079] According to yet a further aspect of the present invention
there is provided stem cell collection bags, separation and washing
buffers supplemented with an effective amount or concentration of a
transition metal chelator which binds copper and/or with Zinc,
which inhibits cell differentiation.
[0080] According to still a further aspect of the present invention
there is provided an assay of determining whether a transition
metal chelator which binds copper causes inhibition or induction of
differentiation, the assay comprising the step of culturing a
population of stem or progenitor cells or cells of a substantially
non-differentiated cell line, in the presence of the transition
metal chelator and monitoring differentiation of the cells, wherein
if differentiation is increased as is compared to non-treated
cells, the transition metal chelator induces differentiation,
whereas if differentiation is decreased or as compared to
non-treated cells, or if differentiation is absent altogether, the
transition metal chelator inhibits differentiation.
[0081] According to another aspect of the present invention there
is provided an assay of determining whether a transition metal
chelator which binds copper causes inhibition or induction of
differentiation, the assay comprising the step of culturing a
population of cells in the presence of the transition metal
chelator and monitoring copper content of the cells, wherein if the
copper content of the cells is increased as is compared to
non-treated cells, the transition metal chelator induces
differentiation, whereas if copper content is decreased as compared
to non-treated cells the transition metal chelator inhibits
differentiation.
[0082] According to yet another aspect of the present invention
there is provided a method of inducing differentiation in a
population of cells, the method comprising the step of providing
the cells with a transition metal chelator which binds copper and
which is effective in inducing cell differentiation.
[0083] According to further features in preferred embodiments of
the invention described below, the cells are in-vivo.
[0084] According to still further features in the described
preferred embodiments the cells are grown ex-vivo.
[0085] According to still further features in the described
preferred embodiments the cells are hematopoietic cells.
[0086] According to still further features in the described
preferred embodiments the cells are selected from the group
consisting of normal cells and cancer cells.
[0087] According to still further features in the described
preferred embodiments the transition metal chelator is a
tripeptide.
[0088] According to still further features in the described
preferred embodiments the transition metal chelator is selected
from the group consisting of GGH, GHL and 1,4,8,11-tetraaza
cyclotetradecane.
[0089] According to still further features in be described
preferred embodiments the transition metal chelator is GGH.
[0090] According to still further features in the described
preferred embodiments the transition metal chelator is a peptide or
a peptide analog.
[0091] According to still further features in the described
preferred embodiments the transition metal chelator includes a
peptide sequence.
[0092] According to still further features in the described
preferred embodiments the peptide sequence is selected from the
group consisting of SEQ ID NOs:1 and 2.
[0093] According to still further features in the described
preferred embodiments the cells are selected from the group
consisting of hematopoietic stem or progenitor cells, neural stem
or progenitor cells, oligodendrocyte stem or progenitor cells, skin
stem or progenitor cells, hepatic stem or progenitor cells, muscle
stem or progenitor cells, bone stem or progenitor cells,
mesenchymal stem or progenitor cells, pancreatic stem or progenitor
cells, stem or progenitor chondrocytes, stroma stem or progenitor
cells, embryonic stem cells and cultured expanded stem or
progenitor cells.
[0094] According to still further features in the described
preferred embodiments the cells are derived from a source selected
from the group consisting of bone marrow, peripheral blood and
neonatal umbilical cord blood.
[0095] According to still further features in the described
preferred embodiments the cells are enriched for hematopoietic
CD.sub.34+ cells.
[0096] According to still further features in the described
preferred embodiments the cells are selected from the group
consisting of non-differentiated stem cells and committed
progenitor cells.
[0097] According to still another aspect of the present invention
there is provided a method of inducing terminal differentiation in
acute leukemic cells, the method comprising the step of providing
the cells with a transition metal chelator which binds copper and
which is effective in inducing cell differentiation.
[0098] According to an additional aspect of the present invention
there is provided a method of induction of differentiation of
non-leukemic hematopoietic progenitor cells, the method comprising
the step of providing the cells with a transition metal chelator
which binds copper and which is effective in inducing cell
differentiation.
[0099] According to still further features in the described
preferred embodiments the cells are selected from the group
consisting of in-vivo and ex-vivo cells.
[0100] According to yet an additional aspect of the present
invention there is provided a method of ex-vivo differentiation of
normal stem cells into lineage committed progenitor cells, the
method comprising the step of providing the cells with a transition
metal chelator which binds copper and which is effective in
inducing cell differentiation.
[0101] According to still an additional aspect of the present
invention there is provided a method of ex-vivo differentiation of
stem cells into dendritic cell committed progenitors, the method
comprising the step of providing the cells with a transition metal
chelator which binds copper and which is effective in inducing cell
differentiation.
[0102] According to a further aspect of the present invention there
is provided a pharmaceutical composition for inducing
differentiation in a population of cells, comprising transition
metal chelator which binds copper and which is effective in
inducing cell differentiation, and a pharmaceutically acceptable
carrier.
[0103] The present invention successfully addresses the
shortcomings of the presently known configurations by providing a
method of propagating cells, yet delaying their differentiation by
Copper deficiency. The present invention further successfully
addresses the shortcomings of the presently known configurations by
providing new means of inducing cell differentiation.
[0104] Additional features and advantages of the method according
to the present invention are described hereinunder.
BRIEF DESCRIPTION OF THE DRAWINGS
[0105] The invention is herein described, by way of example only,
with reference to the accompanying drawings. With specific
reference now to the drawings in detail, it is stressed that the
particulars shown are by way of example and for purposes of
illustrative discussion of the preferred embodiments of the present
invention only, and are presented in the cause of providing what is
believed to be the most useful and readily understood description
of the principles and conceptual aspects of the invention In this
regard, no attempt is made to show structural details of the
invention in more detail than is necessary for a fundamental
understanding of the invention, the description taken with the
drawings making apparent to those skilled in the art how the
several forms of the invention may be embodied in practice.
[0106] In the drawings:
[0107] FIG. 1 shows the short-term effect of TEPA on the
clonlogenic potential of CD.sub.34 cells. Cord blood-derived
CD.sub.34 cells were plated in liquid culture, at 3.times.10.sup.4
cell/ml, in the presence of low dose cytokines: FLT3--5 ng/ml,
SCF--10 ng/ml, IL-6--10 ng/ml, with or without different
concentrations of TEPA. On day 7, aliquots of 0.1 ml were assayed
for colony forming cells by cloning the cells in semi-solid medium
and scoring colonies after 14 days. Results of two independent
experiments are presented.
[0108] FIG. 2 shows the short-term effect of TEPA on total and CD34
cells. Cord blood-derived CD34 cells were plated in liquid culture
in the presence of FL--5 ng/ml, SCF--10 ng/ml, IL-6--10 ng/ml, with
or without of TEPA (20 .mu.M). On day 7, the wells were
demi-depopulated by removal of one half the culture volume and
replacing it with fresh medium and IL-3 (20 ng/ml). On day 14, the
percentage of CD.sub.34 cells (right) and the total cell number
(left) multiplied by the dilution factor were determined.
[0109] FIG. 3 shows the long-term effect of TEPA on cell number and
clonogenic potential of CD.sub.34 cells. Cord blood-derived
CD.sub.34 cells were plated in liquid culture, at 3.times.10.sup.4
cells/ml, in the presence of high dose cytokines: FL--50 ng/ml,
SCF--50 ng/ml, IL-6--50 ng/ml, IL-3--20 ng/ml, G-CSF-10 ng/ml,
EPO--1 U/ml, with or without TEPA (20 .mu.M). On day 4, the
cultures were diluted 1:10 with 0.9 ml fresh medium supplemented
with cytokines and TEPA. On day 7, 14 and 21, the cultures were
demi-depopulated by removal of one half the culture volume and
replacing it with fresh medium, cytokines and TEPA, as indicated.
Cells of the harvested medium were count and aliquots equivalent to
1.times.10.sup.3 initiating cells were cloned in semi-solid medium.
The numbers of cells (up) in the liquid culture and of colonies
(down) in the semi-solid culture, multiplied by the dilution
factors, are represented. * denotes small colonies and cell
clusters.
[0110] FIG. 4 shows the long-term effect of TEPA on CD34 cells
cultured with early cytokines Cord blood-derived CD.sub.34 cells
were plated in liquid culture in the presence of: FL--50 ng/ml,
SCF--50 ng/ml and thrombopoietin (TPO)--20 ng/ml, with or without
TEPA (10 .mu.M). At weekly intervals, the cultures were
demi-depopulated by removal of one half the culture volume and
replacing it with fresh medium cytokines and TEPA, as indicated.
Cells of the harvested medium were count and aliquots equivalent to
1.times.10.sup.3 initiating cells were cloned in semi-solid medium.
The numbers of cells (down) in the liquid culture and of colonies
(up) in the semi-solid culture, multiplied by the dilution factors,
are represented. * denotes that no colonies developed.
[0111] FIG. 5 shows the effect of TEPA on development of erythroid
precursors. Peripheral blood mononuclear cells, obtained from an
adult normal donor, were cultured in the erythroid two-phase liquid
culture system (23-25). The second phase of the culture was
supplemented either without or with 10 .mu.M of TEPA. Cultures were
analyze for total cells and hemoglobin-containing [benzidine
positive (B.sup.+)] cells after 14 days.
[0112] FIGS. 6a-d show the effect of TEPA on cell maturation.
Morphology of cells in long-term (7 weeks) cultures in the absence
(6a and 6c) and presence (6b and 6d) of TEPA is shown. Cytospin
prepared slides were stained with May-Grunwald Giemsa.
Magnifications: 6a and 6b.times.600; 6c and 6d.times.1485.
[0113] FIG 7 shows the effect of transition metal chelators on cell
number and clonogenic of CD.sub.34 cells initiated cultures. Cord
blood-derived CD.sub.34 cells were plated in liquid cultures in the
presence of FL--20 ng/ml, SCF--20 ng/ml, IL--3-20 ng/ml, IL--6-20
ng/ml, and either TEPA--10 .mu.M, captopril (CAP)--10 .mu.M or
Penicillamine (PEN)--10 .mu.M, as indicated. On day 7, cells were
counted and culture aliquots equivalent to 1.times.10.sup.3
initiating cells were plated in semi-solid medium. The bars present
the total cell number (.times.10.sup.3/ml) on day 7 and the number
of colonies per plate 14 days following cloning.
[0114] FIG. 8 shows the effect of Copper on the clonogenic
potential and total cell number of CD.sub.34 cells. Cord
blood-derived CD.sub.34 cells were plated in liquid cultures in the
presence of cytokines: FL--10 ng/ml, SCF--10 ng/ml, IL--3-10 ng/ml,
IL-6--10 ng/ml. Cultures were supplemented with Copper-sulfate--5
.mu.M and TEPA--20 .mu.M, as indicated. On day 7, cells were
counted (down) and aliquots equivalent to 1.times.10.sup.3
initiating cells were plated in semi-solid medium Colonies were
scored after 14 days (up).
[0115] FIG. 9 shows the effect of ions on the clonogenic potential
of cultured CD34 cells. Cord blood-derived CD.sub.34 cells were
plated in liquid cultures in the presence of FL--10 ng/ml, SCF--10
ng/ml, IL--3-10 ng/ml, IL-6--10 ng/ml, and either with or without
TEPA--10 .mu.M. The cultures were supplemented with
Copper-sulfate--5 mM, sodium selenite--5 mM or iron-saturated
transferrin 0.3 mg/ml, as indicated. On day 7, culture aliquots
equivalent to 1.times.10.sup.3 initiating cells were plated in
semi-solid medium. Colonies were scored after 14 days.
[0116] FIG. 10 shows the effect of Zinc on the proliferative
potential of CD.sub.34 cells. Cord blood-derived CD.sub.34 cells
were plated in liquid cultures in the presence of FL--10 ng/ml,
SCF--10 ng/ml, IL-3-10 ng/ml, IL-6-10 ng/ml, and either TEPA--10
.mu.M or Zinc-sulfate--5 mM or both. On day 7, aliquots equivalent
to 1.times.10.sup.3 initiating cells were plated in semi-solid
medium. Colonies were scored after 14 days.
[0117] FIGS. 11a-c show the effect of TEPA on long-term CD.sub.34
cultures. Cultures were initiated with 104 cord blood-derived
CD.sub.34 cells by plating purified cells in liquid medium in the
presence of SCF, FLT3 and IL-6 (50 ng/ml each) and IL-3 (20 ng/ml)
with or without TEPA (10 .mu.M). At weekly intervals, the cultures
were demi-depopulated by removal of half the cells followed by
addition of fresh medium, cytokines and TEPA. At the indicated
weeks, cells were counted and assayed for colony forming cells
(CFUc) by cloning in semi-solid medium. CFUc frequency was
calculated as number of CFUc per number of cells. Cloning of
purified CD.sub.34 cells on day 1 yielded 2.5.times.10.sup.3 CFUc
per 10.sup.4 initiating cells. * denotes that no colonies
developed.
[0118] FIGS. 12-14 show the effect of TEPA on cell proliferation,
CFUc and CFUc frequency in the presence of different combination of
early cytokines. Cord blood-derived CD.sub.34 cells were cultured
as detailed in FIGS. 11a-c in liquid medium in the presence of SCF,
FLT3 and IL-6 (SCF, FLT, 11-6), each at 50 ng/ml, with or without
TEPA (10 .mu.M). In addition, cultures were supplemented with
either IL-3 (20 ng/ml), TPO (50 ng/ml) or both, as indicated. At
weekly intervals, the cultures were demi-depopulated and
supplemented with fresh medium, cytokines and TEPA. At the
indicated weeks, the cells were counted (FIG. 12), assayed for CFUc
(FIG. 13) and the CFUc frequency calculated (FIG. 4). * denotes
that no colonies developed.
[0119] FIG. 15 shows the effect of G-CSF and GM-CSF on CFUc
frequency of control and TEPA-supplemented CD.sub.34 cultures. Cord
blood-derived CD.sub.34 cells were cultured as detailed in FIGS.
11a-c. After one week, half of the control and TEPA cultures were
supplemented with the late-acting cytokines G-CSF and GM-CSF (10
ng/lm each). At weekly intervals, the cultures were
demi-depopulated and supplemented with fresh medium, cytokines and
TEPA. At weeks 3, 4 and 5, cells were counted, assayed for CFUc and
CFUc frequency calculated.
[0120] FIGS. 16-17 show the effect of partial or complete
medium+TEPA change on longterm cell proliferation and CFUc
production. Cord blood-derived CD.sub.34 cells were cultured as
detailed in FIGS. 11a-c. At weekly intervals, the cultures were
demi-depopulated and supplemented with fresh medium, cytokines and
TEPA. At weekly intervals, half of the culture content (cells and
supernatant) was removed and replaced by fresh medium, cytokines
with or without TEPA (partial change). Alternatively, the whole
content of the culture was harvested, centrifuged, the supernatant
and half of the cells discarded and the remaining cells recultured
in fresh medium, cytokines with or without TEPA (complete change)
At the indicated weeks the number of cells (FIG. 16) and CFUc (FIG.
17) were determined.
[0121] FIG. 18 show the effect of TEPA on CD.sub.34 cell expansion.
Cord blood-derived CD.sub.34 cells were cultured as detailed in
FIGS. 11a-c. At weeks 1, 2 and 3, CD.sub.34.sup.+ cells were
enumerated by flow cytometry. * denotes that no colonies
developed.
[0122] FIG. 19 shows the effect of delayed addition of TEPA on CFUc
frequency. Cord blood-derived CD.sub.34 cells were cultured as
detailed in FIGS. 11a-c. TEPA (10 .mu.M) was added at the
initiation of the cultures (day 1) or 6 days later. At weekly
intervals, the cultures were demi-depopulated and supplemented with
fresh medium, cytokines and TEPA. At weeks 3, 4 and 5, cells were
counted, assayed for CFUc and the CFUc frequency was
calculated.
[0123] FIG. 20 show the effect of short-term preincubation with a
single cytokine on long-term CFUc production. Cord blood-derived
CD.sub.34 cells were cultured as detailed in FIGS. 11a-c. Cultures
were supplemented on day 1 with or without TEPA (10 .mu.M) and with
SCF, FLT3, IL-6, (50 ng/ml each) and IL-3 (20 ng/ml).
Alternatively, cultures were supplemented on day 1 with TEPA (10
ELM) and FLT3 (50 ng/ml) as a single cytokine. SCF, IL-6 (50 ng/ml
each) and IL-3 (20 ng/ml) were added to these cultures at day 2. At
weekly intervals, the cultures were demi-depopulated and
supplemented with fresh medium, cytokines and TEPA. At the
indicated weeks cells were assayed for CFUc.
[0124] FIGS. 21a-b show the effect of polyamine chelating agents on
CD.sub.34 cell cultures. Cord blood-derived CD34 cells were
cultured as detailed in FIGS. 11a-c. The polyamine chelating agents
tetraethylenepentamine (TEPA), pentaethylenehexamine (PEHA),
ethylenediamine (EDA) or triethylene-tetramine (TETA) were added,
at different concentrations. At weekly intervals, the cultures were
demi-depopulated and supplemented with fresh medium, cytokines and
chelators At weeks 3, 4, 6 and 7, cells were counted and assayed
for CFUc. The results presented are for concentrations with optimal
activity: TEPA--40 .mu.M, PEHA--40 .mu.M, EDA--20 .mu.M and
TETA--20 .mu.t.
[0125] FIGS. 22a-b show the effect of transition metal chelating
agents on CD.sub.34 cell cultures. Cord blood-derived CD.sub.34
cells were cultured as detailed in FIGS. 11a-c. The chelators
Captopril (CAP), Penicilamine (PEN) and TEPA were added, at
different concentrations. At weekly intervals, the cultures were
demi-depopulated and supplemented with fresh medium, cytokines and
chelators. At the weeks 4, 5 and 7, cells were counted and assayed
for CFUc. The results presented are for concentrations with optimal
activity: TEPA--10 .mu.M, PEN--5 .mu.M and CAP--40 .mu.M.
[0126] FIGS. 23a-b show the effect of Zinc on CD.sub.34 cell
cultures. Cord blood-derived CD.sub.34 cells were cultured as
detailed in FIGS. 11a-c. Zinc (Zn) was added, at different
concentrations, on day 1. At weekly intervals, the cultures were
demi-depopulated and supplemented with fresh medium, cytokines and
Zn. At the weeks 4, 5 and 7, cells were counted and assayed for
CFUc.
[0127] FIG. 24 shows the effect of TEPA on peripheral blood derived
CD.sub.34 cell cultures. Peripheral blood-derived CD.sub.34 cells
were cultured as detailed in FIGS. 11a-c. Cultures were
supplemented with or without TEPA. At weekly intervals, the
cultures were demi-depopulated and supplemented with fresh medium
and TEPA. At weeks 1 and 4, and, cells were assayed for CFUc. *
denotes that no colonies developed.
[0128] FIGS. 25a-b show the effect of Copper-chelating peptides on
CD.sub.34.sup.+ cell cultures. Cultures were initiated with
10.sup.4 cord blood-derived CD.sub.34.sup.+ cells by plating
purified cells in liquid medium in the presence of SCF, FLT3 and
IL-6 (50 ng/ml each) and the Copper-binding peptides, Gly-Gly-His
(GGH) or Gly-His-Lys (GHL) (10 .mu.M each), or the late-acting
cytokines granulocyte-CSF (G-CSF) and granulocyte macrophage-CSF
(GM-CSF) (10 ng/ml each). At weekly intervals, the cultures were
demi-depopulated and supplemented with fresh medium, cytokines and
the peptides After 7 weeks, cells were counted (FIG. 25a) and
assayed for colony forming cells in culture (CFUc, FIG. 25b).
[0129] FIG. 26 shows the chemical structure of transition metal
chelators used in an assay according to the present invention,
which can be used to determine the potential of any chelator to
arrest or induce cell differentiation.
[0130] FIG. 27a-f show photographs of hepatocytes cultures that
were ex-vivo expanded with (27a-d) or without (27e-f) TEPA for five
weeks.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0131] The present invention is of methods of controlling
proliferation and/or modulating differentiation of stem and
progenitor cells, which can be used to provide a therapeutical
ex-vivo cultured cell preparation which includes a large population
of cells, in which differentiation was inhibited while cell
expansion propagated, and which can alternatively he used to induce
cell differentiation Specifically, the present invention can be
used, on one hand, to provide expanded populations of stem cells,
as well as progenitor cells, which can be used for, for example,
hematopoietic cell transplantations, or the generation of stem or
progenitor cells suitable for genetic manipulations, which may be
used for gene therapy, and new treatment means for diseases, such
as, but not limited to, .beta.-hemoglobinopathia, or alternatively,
the present invention can be used to provide a large population of
differentiated cells, which can be used, for example, for cell
transplantations and for genetic manipulations, which may be used
for gene therapy.
[0132] Thus, the present invention relates to a method of
controlling proliferation and differentiation of stem and
progenitor cells. More particularly, in one aspect, the present
invention relates to a method of imposing proliferation yet
restricting differentiation of stem and progenitor cells, whereas,
in another aspect, the present invention relates to a method of
inducing differentiation of stem and progenitor cells by apparently
modifying the availability of transition metals, Copper in
particular. In both case, the present invention is effected by
modifying (decreasing or increasing) the availability of transition
metals, Copper in particular, to cells undergoing cell expansion
according to the first aspect of the invention or to cells
undergoing differentiation, according to the second aspect of the
present invention.
[0133] The principles and operation of the methods according to the
present invention may be better understood with reference to the
drawings and accompanying descriptions and examples.
[0134] Before explaining at least one embodiment of the invention
in detail, it is to be understood that the invention is not limited
in its application to the details of construction and the
arrangement of the components set forth in the following
description or illustrated in the drawings. The invention is
capable of other embodiments or of being practiced or carried out
in various ways Also, it is to be understood that the phraseology
and terminology employed herein is for the purpose of description
and should not be regarded as limiting.
[0135] In the course of the present study it was found that a
series of chemical agents that bind (chelate) Copper and other
transition metals, or that interfere with Copper metabolism can
reversibly inhibit (delay) the process of differentiation of stem
cells as well as intermediate and late progenitor cells and thereby
stimulate and prolong the phase of active cell proliferation.
[0136] This newly discovered effect of transition metal depletion
was utilized for maximizing the ex-vivo expansion of various types
of cells including hematopoietic cells, hepatocytes and embryonic
stem cells. Such ex-vivo expanded cells can be applied in several
clinical situations. The following lists few.
[0137] Hematopoietic Cell Transplantation:
[0138] Transplantation of hematopoietic cells has become the
treatment of choice for a variety of inherited or malignant
diseases While early transplantation procedures utilized the entire
bone marrow (BM) population, recently, more defined populations,
enriched for stem cells (CD.sub.34.sup.+ cells) have been used
(1).
[0139] In addition to the marrow, such cells could be derived from
other sources such as peripheral blood (PB) and neonatal umbilical
cord blood (CB) (2). Compared to BM, transplantation with PB cells
shortens the period of pancytopenia and reduces the risks of
infection and bleeding (3-5).
[0140] An additional advantage of using PB for transplantation is
its accessibility. The limiting factor for PB transplantation is
the low number of circulating pluripotent stem/progenitor
cells.
[0141] To obtain enough PB-derived stem cells for transplantation,
these cells are "harvested" by repeated leukapheresis following
their mobilization from the marrow into the circulation by
treatment with chemotherapy and cytokines (3-4). Such treatment is
obviously not suitable for normal donors.
[0142] The use of ex-vivo expended stem cells for transplantation
has the following advantages (2, 6-7).
[0143] It reduces the volume of blood required for reconstitution
of an adult hematopoietic system and may obviate the need for
mobilization and leukapheresis (3).
[0144] It enables storage of small number of PB or CB stem cells
for potential future use.
[0145] In the case of autologous transplantation of patients with
malignancies, contaminating tumor cells in autologous infusion
often contribute to the recurrence of the disease (3). Selecting
and expanding CD.sub.34.sup.+ stem cells will reduce the load of
tumor cells in the final transplant.
[0146] The cultures provide a significant depletion of T
lymphocytes, which may be useful in the allogeneic transplant
setting for reducing graft-versus-host disease.
[0147] Clinical studies have indicated that transplantation of
ex-vivo expanded cells derived from a small number of PB
CD.sub.34.sup.+ cells can restore hematopoiesis in patients treated
with high doses of chemotherapy, although the results do not allow
yet firm conclusion about the long term in-vivo hematopoietic
capabilities of these cultured cells (3-4).
[0148] For successful transplantation, shortening of the duration
of the cytopenic phase, as well as longterm engraftment, is
crucial. Inclusion of intermediate and late progenitor cells in the
transplant could accelerate the production of donor-derived mature
cells and shortens the cytopenic phase. It is important, therefore,
that ex-vivo expanded cells will include, in addition to stem
cells, more differentiated progenitors in order to optimize
short-term recovery and long term restoration of hematopoiesis.
Expansion of intermediate and late progenitor cells, especially
those committed to the neutrophilic and megakayocytic lineages,
concomitant with expansion of stem cells, should serve this purpose
(8).
[0149] Such cultures may be useful not only in restoring
hematopoiesis in completely bone marrow ablated patients but also
as supportive measure for shortening bone marrow recovery following
conventional radio- or chemo-therapies.
[0150] Prenatal Diagnosis of Genetic Defects in Scarce Cells:
[0151] Prenatal diagnosis involved the collection of embryonic
cells from a pregnant woman and analysis thereof for genetic
defects. A preferred, non-invasive, way of collecting embryonic
cells involves separation of embryonic nucleated red blood cell
precursors that infiltrated into the maternal blood circulation.
However, being very scarce, such cells should undergo cell
expansion prior to analysis. The present invention therefore offers
means to expand embryonic cells for prenatal diagnosis.
[0152] Gene Therapy:
[0153] For a successful long-term gene therapy a high frequency of
genetically modified stem cells that have integrated the transgene
into their genome is an obligatory requirement. In the BM tissue,
while the majority of the cells are cycling progenitors and
precursors, the stem cells constitute only a small fraction of the
cell population and most of them are in a quiescent, non-cycling
state. Viral-based (e.g., retroviral) vectors require active cell
division for integration of the transgene into the host genome. For
these reasons gene transfer into fresh BM stem cells is very
inefficient. The ability to expand a purified population of stem
cells and to regulate their cell division ex-vivo would permit
increased probability of their genetic modification (9).
[0154] Adoptive Immunotherapy:
[0155] Ex-vivo expanded, defined lymphoid subpopulations have been
studied and used for adoptive immunotherapy of various
malignancies, immunodeficiency, viral and genetic diseases
(10-12).
[0156] The treatment enhances the required immune response or
replaces deficient functions. This approach was pioneered
clinically by Rosenberg et al. (13) using a large number of
autologous ex-vivo expanded non-specific killer T cells, and
subsequently ex-vivo expanded specific tumor infiltrating
lymphocytes.
[0157] It was also shown that functionally active
antigen-presenting cells can be grown from a starting population of
CD.sub.34.sup.+ PB cells in cytokine-supported cultures. These
cells can present soluble protein antigens to autologous T cells
in-vitro and, thus, offer new prospects for the immunotherapy of
minimal residual disease after high dose chemotherapy. Ex-vivo
expansion of antigen-presenting dendritic cells was also studied
(14-16).
[0158] Ex-vivo Expansion of Non-Hematopoietic Stem and Progenitor
Cells:
[0159] For example, ex-vivo expansion of neural stem cells or
oligodendrocyte progenitors, etc.
[0160] Myelin disorders form an important group of human
neurological diseases that are as yet incurable. Progress in animal
models, particularly in transplanting cells of the oligodendrocyte
lineage, has resulted in significant focal remyelination and
physiological evidence of restoration of function (36). Future
therapies could involve both transplantation and promotion of
endogenous repair, and the two approaches could be combined with
ex-vivo manipulation of the donor tissue.
[0161] U.S. Pat. No. 5,486,359 teaches isolated human mesenchymal
stem cells which can differentiate into more than one tissue type
(e.g. bone, cartilage, muscle or marrow stroma) and a method for
isolating, purifying, and culturally expanding human mesenchymal
stem cells.
[0162] U.S. Pat. No. 5,736,396 teaches methods for in-vitro or
ex-vivo lineage-directed induction of isolated, culture expanded
human mesenchymal stem cells comprising the steps of contacting the
mesenchymal stem cells with a bioactive factor effective to induce
differentiation thereof into a lineage of choice. Further disclosed
is a method which also includes introducing such culturally
expanded lineage-induced mesenchymal stem cells into a host from
which they have originated for purposes of mesenchymal tissue
regeneration or repair.
[0163] U.S. Pat. No. 4,642,120 teaches compositions for repairing
defects of cartilage and bones These are provided in gel form
either as such, or embedded in natural or artificial bones. The gel
comprises certain yes of cells. These may he committed embryonal
chondocytes or any kind of mesenchyme originated cells which
potentially can be converted to cartilage cells, generally by the
influence of chondrogenic inducing factors, in combination with
fibrinogen, antiprotease and thrombin.
[0164] U.S. Pat. No. 5,654,186 teaches that blood-borne mesenchymal
cells proliferate in culture, and in-vivo, as demonstrated in
animal models, are capable of migrating into wound sites from the
blood to form skin.
[0165] U.S. Pat. No. 5,716,411 teaches to a method of skin
regeneration of a wound or burn in an animal or human This method
comprises the steps of initially covering the wound with a collagen
glycosaminoglycan matrix, allowing infiltration of the grafted GC
matrix by mesenchymal cells and blood vessels from healthy
underlying tissue and applying a cultured epithelial autograft
sheet grown from epidermal cells taken from the animal or human at
a wound-free site on the animal's or human's body surface. The
resulting graft has excellent take rates and has the appearance,
growth, maturation and differentiation of normal skin.
[0166] U.S. Pat. No. 5,716,616 teaches methods of treating patients
who are suffering from a disease, disorder or condition
characterized by a bone cartilage or lung defects. The methods
comprising the step of intravenous administration of stromal cells
isolated from normal syngeneic individuals or intravenous
administration of stromal cells isolated from the patient
subsequent to correction of the genetic defect in the isolated
cells. Methods of introducing genes into a recipient individual are
also disclosed. The methods comprise the steps of obtaining a bone
marrow sample from either the recipient individual or a matched
syngeneic donor, isolating adherent cells from the sample,
transfecting the adherent cells that were isolated from the
recipient or a matched syngeneic donor with a gene and
administering the transfected adherent cells to the recipient
individual intravenously. Compositions that comprise isolated
stromal cells that include exogenous genes operably linked to
regulatory sequences are disclosed.
[0167] In each of the above examples, non-hematopoietic stem and
progenitor cells are used as an external source of cells for
replenishing missing or damaged cells of an organ. Such use
requires cell expansion prior to differentiation in order to first
obtain the required cell mass. It is in this step where the method
of the present invention can become highly effective and useful
while implementing any of the methods disclosed in the above U.S.
patents.
[0168] Additional Examples for Both ex-vivo and in-vivo
Applications:
[0169] skin regeneration, hepatic regeneration, muscle regeneration
and bone growth in osteoporosis.
[0170] Mobilization of Bone Marrow Stem Cells into the Peripheral
Blood (Peripheralization):
[0171] The discovery of the effect of transition metal chelators
could also be applied in-vivo. As mentioned above, PB-derived stem
cells for transplantation are "harvested" by repeated leukapheresis
following their mobilization from the marrow into the circulation
by treatment with chemotherapy and cytokines (3-4).
[0172] The use of chemotherapy is, of course, not suitable for
normal donors. Administration of transition metal chelators, such
as TEPA, into the donor could increase the marrow stem cell pool,
which is then mobilized into the periphery by endogenous or
injected G-CSF
[0173] Leukemia:
[0174] Unlike normal hematopoiesis, in leukemia, the processes of
proliferation and differentiation are uncoupled; the malignant
cells are unable to differentiate and consequently maintain
continuous proliferation ability.
[0175] Understanding of the molecular events driving the uncoupling
of the proliferation and differentiation processes of normal
progenitors following transition metals depletion, in particular
Copper, may shed light on the cellular processes involved in the
development of leukemia.
[0176] Stimulation of Fetal Hemoglobin Production:
[0177] Increased fetal hemoglobin has been shown to ameliorate the
clinical symptoms in patients with .beta.-hemoglobinopathies such
as sickle cell anemia and .beta.-thalassemia (38).
[0178] Fetal hemoglobin, which normally comprises about 1% of the
total hemoglobin, becomes elevated in accelerated erythropoiesis
(e.g., following acute hemolysis or hemorrhage or administration of
erythropoietin) (35).
[0179] It has been suggested that this phenomenon is associated
with acceleration/differentiation process of the erythroid
precursors (37).
[0180] Administration of transition metal chelators such as TEPA to
patients with .beta.-hemoglobinopathies might first increase and
synchronize their early erythroid progenitor pool (by blocking
differentiation).
[0181] Following cessation of administration of the drug and its
removal from the body, this early population then might undergo
accelerated maturation which may result in elevated production of
fetal hemoglobin.
[0182] Thus, according to one aspect of the present invention there
is provided a method of expanding a population of cells, while at
the same time, inhibiting differentiation of the cells. The method
includes the step of providing the cells with conditions for cell
proliferation and, at the same time, reducing a capacity of the
cells in utilizing transition metals, such as Copper.
[0183] Reducing the capacity of the cells in utilizing transition
metals may be effected, for example, either by depletion thereof
(e.g., via suitable chelators) or by interference in their
metabolism (e.g., via addition of Zinc ions).
[0184] As used herein the term "inhibiting" refers to slowing,
decreasing, delaying, preventing or abolishing.
[0185] As used herein the term "differentiation" refers to change
from relatively generalized to specialized kinds during
development. Cell differentiation of various cell lineages is a
well documented process and requires no further description herein.
As used herein th term differentiation is distinct from maturation
which is a process, although some times associated with cell
division, in which a specific cell type mature to function and then
dies, e.g., via programmed cell death.
[0186] According to a preferred embodiment of the present invention
the cells to be expanded are present in-vivo. In this case the
conditions for cell proliferation are naturally provided. Whereas,
reducing the capacity of the cells in utilizing transition metals,
such as, but not limited to, Copper is effected by administering a
transition metal, e.g., Copper, chelator, Zinc ions, or both.
[0187] Administration of the transition metal chelator and/or Zinc
ions may be by a pharmaceutical composition including same, which
may further include thickeners, carriers, buffers, diluents,
surface active agents, preservatives, and the like, all as well
known in the art.
[0188] The pharmaceutical composition may be administered in either
one or more of ways depending on whether local or systemic
treatment is of choice, and on the area to be treated.
Administration may be done topically (including ophtalmically,
vaginally, rectally, intranasally), orally, by inhalation, or
parenterally, for example by intravenous drip or intraperitoneal,
subcutaneous, intramuscular or intravenous injection.
[0189] Formulations for topical administration may include but are
not limited to lotions, ointments, gels, creams, suppositories,
drops, liquids, sprays and powders. Conventional pharmaceutical
carriers, aqueous, powder or oily bases, thickeners and the like
may be necessary or desirable.
[0190] Compositions for oral administration include powders or
granules, suspensions or solutions in water or non-aqueous media,
sachets, capsules or tablets. Thickeners, diluents, flavorings,
dispersing aids, emulsifiers or binders may be desirable.
[0191] Formulations for parenteral administration may include but
are not limited to sterile solutions which may also contain
buffers, diluents and other suitable additives.
[0192] Dosing is dependent on seventy and responsiveness of the
condition to be treated, but will normally be one or more doses per
day, with course of treatment lasting from several days to several
months or until a cure is effected or a diminution of disease state
is achieved. Persons ordinarily skilled in the art can easily
determine optimum dosages, dosing methodologies and repetition
rates. Slow release administration regime may be advantageous in
some applications.
[0193] According to another preferred embodiment of the present
invention the cells to be expanded are present ex-vivo.
[0194] As used herein the term "ex-vivo" refers to cells removed
from a living organism and are propagated outside the organism
(e.g., in a test tube). As used herein, the term "ex-vivo",
however, does not refer to cells known to propagate only in-vitro,
such as various cell lines (eg., HL-60, MEL, HeLa, etc.).
[0195] Providing the ex-vivo grown cells with the conditions for
cell proliferation include providing the cells with nutrients and
preferably with one or more cytokines. Again, reducing the capacity
of the cells in utilizing transition metals, such as Copper is
effected by a suitable transition metal, e.g., Copper, chelator
and/or Zinc ions.
[0196] Final concentrations of the chelator and/or Zinc ions may
be, depending on the specific application, in the micromolar or
millimolar ranges. For example, within about 0.1 .mu.M to about 100
mM, preferably within about 4 .mu.M to about 50 mM, more preferably
within about 5 .mu.M to about 40 mM.
[0197] According to a preferred embodiment of the invention the
chelator is a polyamine chelating agent, such as, but not limited
to ethylendiamine, diethylenetriamine, triethylenetetramine,
triethylenediamine, tetraethylenepentamine, aminoethylethanolamine,
aminoethylpiperazine, pentaethylenehexamine,
triethylenetetramine-hydroch- loride,
tetraethylenepentamine-hydrochloride, pentaethylenehexamine-hydroc-
hloride, tetraethylpentamine, captopril, penicilamine,
N,N'-bis(3-aminopropyl)-1,3-propanediamine, N,N,Bis (2 animoethyl)
1,3 propane diamine, 1,7-dioxa-4,10-diazacyclododecane,
1,4,8,11-tetraaza cyclotetradecane-5,7-dione,
1,4,7-triazacyclononane trihydrochloride,
1-oxa-4,7,10-triazacyclododecane, 1,4,8,12-tetraaza
cyclopentadecane or 1,4,7,10-tetraaza cyclododecane, preferably
tetraethylpentamine. The above listed chelators are known in their
high affinity towards Copper ions. However, these chelators have a
substantial affinity also towards other transition metals (39). The
latter is incorporated by reference as if fully set forth
herein.
[0198] According to another preferred embodiment of the invention
the cytokines are early acting cytokines, such as, t not limited
to, stem cell factor, FLT3 ligand, interleukin-6, thrombopoietin
and interleukin-3, and/or late acting cytokines, such as, but not
limited to, granulocyte colony stimulating factor,
granulocyte/macrophage colony stimulating factor and
erythiropoietin.
[0199] The cells may be of any cell lineage including, but not
limited to, hematopoietic stem or progenitor cells, neural stem or
progenitor cells, oligodendrocyte stem or progenitor cells, skin
stem or progenitor cells, hepatic stem or progenitor cells, muscle
stem or progenitor cells, bone stem or progenitor cells,
mesenchymal stem or progenitor cells, pancreatic stem or progenitor
cells, chondrocyte stem or progenitor cells, stroma stem or
progenitor cells or embryonal stem cells.
[0200] Depending on the application, hematopoietic cells may be
obtained for ex-vivo expansion according to the method of the
present invention from bone marrow, peripheral blood, or neonatal
umbilical cord blood.
[0201] Preferably, the hematopoietic cells are enriched for
hematopoietic CD.sub.34+ cells (i.e., stem cells). Enriching the
fraction of stem cells may be effected by cell sorting, as well
known in the alt.
[0202] The cells expanded according to the present invention may be
either non-differentiated stem cells or committed progenitor cells.
Stem cells are known for many cell lineages, including, but not
limited to, those lineages listed hereinabove. These cells are
characterize(by being the most undifferentiated cells of the
lineage. Progenitor cells, on the other hand, are more
differentiated, as they are already committed to a specific
differentiation path within the cell lineage.
[0203] Further according to this aspect of the present invention
there is provided a method of hematopoietic cells transplantation.
The method includes the following steps. First, hematopoietic cells
to be transplanted are obtained from a donor. Second, the cells are
provided ex-vivo with conditions for cell proliferation and, at the
same time, reducing a capacity of the cells in utilizing transition
metals, Copper in particular, thereby expanding a population of the
cells, while at the same time, inhibiting differentiation of the
cells. Finally, the cells are transplanted to a patient. In a case
of an autologous transplantation the donor and the patient are a
single individual. The cells may be obtained from peripheral blood,
bone marrow or neonatal umbilical cord blood. They are preferably
enriched for stem cells or for progenitor cells (e.g., by cell
sorting) prior to, or after, cell expansion.
[0204] Further according to this aspect of the present invention
there is provided a method of genetically modifing (transducing,
transfecting, transforming) stem cells with an exogene (transgene).
The method includes the following steps. First, stem cells to be
genetically modified are obtained. Second, the cells are provided
ex-vivo with conditions for cell proliferation and, at the same
time, for reducing a capacity of the cells in utilizing transition
metals, Copper In particular, thereby expanding a population of the
cells, while at the same time, inhibiting differentiation of the
cells. Third, the cells are genetically modified with the exogene.
Genetic modification methods are well known in the art and require
no further description herein. Examples of genetic modification
protocols are found in many laboratory manuals including Sambrook,
J., Fritsch, E. F., Maniatis, T. (1989) Molecular Cloning. A
Laboratory Manual. Cold Spring Harbor Laboratory Press, New York.
Genetic modification is preferably effected by a vector including
the exogene.
[0205] Further according to this aspect of the present invention
there is provided a method of adoptive immunotherapy. The method
includes the following steps. First, progenitor hematopoietic cells
from a patient are obtained. Second, the cells are provided ex-vivo
with conditions for cell proliferation and, at the same time, for
reducing a capacity of the cells in utilizing transition metals,
Copper in particular, thereby expanding a population of the cells,
while at the same time, inhibiting differentiation of the cello
Finally, the cells are transplanted into the patient.
[0206] Further according to this aspect of the present invention
there is provided a method of mobilization of bone marrow stem
cells into the peripheral blood of a donor for harvesting the
cells. The method includes the following steps. First, the donor is
administered with an agent for reducing a capacity of the cells in
utilizing transition metals, Copper in particular, thereby
expanding a population of stem cells, while at the same time,
inhibiting differentiation of the stem cells. Second, the cells are
harvested by leukapheresis. Administering the donor a cytokine
(early and/or late acting cytokine) is preferred to enhance
mobilization. The agent is preferably a transition metal chelator
and/or Zinc ions.
[0207] Further according to this aspect of the present invention
there is provided a method of decelerating
maturation/differentiation of erythroid precursor cells for the
treatment of .beta.-hemoglobinopathic patients. The method includes
the step of administering to the patient an agent for reducing a
capacity of the cells in utilizing transition metals, Copper in
particular, thereby expanding a population of stem cells, while at
the same time, inhibiting differentiation of the stem cells, such
that upon natural removal of the agent from the body, the stem
cells undergo accelerated maturation resulting in elevated
production of fetal hemoglobin.
[0208] Further according to this aspect of the present invention
there is provided a therapeutical ex-vivo cultured cell
preparation. The preparation includes ex-vivo cells propagated in
the presence of an agent for reducing a capacity of the cells in
utilizing transition metals, Copper in particular, thereby
expanding a population of the cells, while at the same time,
inhibiting differentiation of the cells.
[0209] Further while reducing the present invention to practice it
was found that a series of other chemical agents that bind
(chelate) Copper and other transition metals and that enhance
Copper uptake by cells can reversibly induce or facilitate the
process of differentiation of stem cells as well as intermediate
and late progenitor cells and thereby impose or accelerate cell
differentiation.
[0210] This newly discovered effect was utilized for maximizing
ex-vivo differentiation of various types of cells.
[0211] It was previously shown and it is described hereinabove and
exemplified in the Examples section that follows, that a group of
Copper-chelating agents, which includes polyamines such as TEPA or
chelators such as Penicillamine and Captopril, delays cell
differentiation and thereby support continuous cell proliferation
and long-term generation of stem and/or progenitor cells of
different types. These effects could be overridden by excess of
Copper, strongly suggesting that they involve Copper chelation and
subsequent Copper prevention.
[0212] However now it is disclosed that a second group of
transition metal, e.g., Copper chelators, which includes the
Copper-binding peptides GGH and GHL (SEQ ID NOs:1 and 2) and the
polyamine 1,4,8,11-tetraaza cyclotetradecane, accelerate cell
differentiation and thereby limits cell proliferation. The latter
effects were also observed, with a similar kinetics, when the
cultures were supplemented with late-acting cytokines such as G-
and GM-CSF which are known for their ability to accelerate cellular
differentiation. Copper salt (1 .mu.M) had a similar effect.
[0213] These results which are presented in the Examples section
that follows show that compounds of this group of chelators, i.e.,
differentiation inducing chelators, as opposed to the former group
of chelators, which are differentiation inhibiting chelators,
affect the cultures by improving Copper availability to the
cellular differentiation mechanism.
[0214] It is at present a working hypothesis that the two
contrasting effects of Copper-binding compounds are caused by their
different Copper binding affinities; differentiation-inhibiting
compounds bind Copper with high affinity, substantially
irreversibly, and thereby function as chelators that decrease the
cellular Copper content, while differentiation-enhancing compounds
bind Copper reversibly (with low affinity) and assist in delivering
Copper to cellular sites where it is required for differentiation.
This hypothesis is not intended to be limiting to the broad scope
of the present invention.
[0215] The biological properties of the differentiation inducing
chelators according to the present invention can be used in several
clinical settings, as follows:
[0216] Induction of Terminal Differentiation in Acute Leukemic
Cells:
[0217] The current approach to the treatment of leukemia is based
on killing the malignant cells by chemo- or radiotherapy. This
treatment is not specific for malignant cells and affects normal
cells as well. Indeed, this approach is limited by the toxicity of
the treatment to a variety of normal tissues. Since acute leukemia
involves a block in cell differentiation, an alternative approach
would be to induce the leukemic cells to undergo differentiation
which is associated with the loss of leukemogenicity.
[0218] Fibach et al. (54) showed that some myeloid leukemia
undifferentiated cells respond to differentiation-inducing agents
and undergo differentiation into mature, functional, non-dividing
granulocytes or macrophages, and thereby, lose their leukemogenic
potential. This inducer was identified as Interleukin-6. Although
originally purified as a differentiation factor for a mouse myeloid
leukemic cell line, it was also found to function as an early
hematopoietic growth factor for normal cells.
[0219] The differentiation inducing chelators according to this
aspect of the present invention were found to induce
differentiation and inhibit proliferation of both human and murine
established leukemic cell lines and of freshly explanted cells from
acute and chronic human myeloid leukemias. Blast cells lose their
leukemic phenotype and turn into functional, non-dividing
macrophages.
[0220] The effect of the differentiation inducing chelators on
leukemic cells makes them potentially useful in the treatment of
myeloid leukemias in three clinical settings: (a) for induction of
remission, either by itself or in combination with other
hematopoietic factors or low-dose chemotherapy, using
"differentiation-inducing therapy" as the main modality; (b) for
maintenance of the remission state; and (c) in autologous
transplantation for either ex-vivo or in-vivo purging of residual
leukemic cells.
[0221] Induction of Differentiation of Non-Leukemic Hematopoietic
Progenitors:
[0222] Several non leukemic hematological pathological conditions
involve a block in cell differentiation These include "maturation
arrest", either idiopathic or drug-induced or in situations like
red cell aplasia and congenital neutropenia. The differentiation
inducing chelators according to this aspect of the present
invention may be useful in these conditions in promoting cell
differentiation.
[0223] Ex-vivo Differentiation of Normal Stem Cells into Lineage
Committed Progenitors:
[0224] For successful transplantation, shortening of the duration
of the cytopenic phase, as well as long-term engraftment, is
crucial Inclusion of intermediate and late progenitor cells in the
transplant could accelerate the production of donor-derived mature
cells and shortens the cytopenic phase It is important, therefore,
that ex-vivo expanded cells will include, in addition to stem
cells, more differentiated progenitors, especially those committed
to the neutrophilic and megakayocytic lineages, in order to
optimize short-term recovery and long term restoration of
hematopoiesis. The differentiation inducing chelators according to
this aspect of the present invention can serve this purpose
[0225] Ex-vivo Differentiation of Stem Cells into Dendritic Cell
Committed Progenitors:
[0226] Dendritic cells are "professional" immunostimulatory,
antigen-presenting cells. Various studies have suggested the
potential use of dendritic cells in immunotherapy. This modality
involves infusion of dendritic cells pulsed in-vivo with tumor
antigens as therapeutic vaccines, as well as using dendritic cells
for priming tumor antigen specific T cells in-vivo for use in
adoptive T cell therapy (55). The differentiation inducing
chelators according to this aspect of the present invention may
have an effect on the differentiation of these cells.
[0227] Thus, according to this aspect of the present invention
there is provided a method of in-vivo or ex-vivo induction of
differentiation in a population of cells by providing the cells
with a transition metal, e.g., Copper, chelator effective in
inducing cell differentiation. The method according to this aspect
of the present invention can, for example, be used for (i)
induction of terminal differentiation in acute leukemic cells; (ii)
induction of differentiation of non-leukemic hematopoietic
progenitors; (iii) ex-vivo differentiation of normal stem cells
into lineage committed progenitors; and/or (iv) ex-vivo
differentiation of stem cells into dendritic cell committed
progenitors.
[0228] According to a preferred embodiment of this aspect of the
present invention the cells are hematopoietic cells. Induced
differentiation of hematopoietic cells by transition metal
chelators is exemplified in the Examples section hereinunder. The
cells differentiating by means of a transition metal chelator
according to this aspect of the present invention can be normal
cells or cancer cells. Thus, cells according to this aspect of the
present invention can be derived, for example, from a source such
as bone marrow, peripheral blood and neonatal umbilical cord blood.
According to an embodiment of this aspect of the present invention
the cells are enriched for hematopoietic CD.sub.34+ cells.
According to another embodiment the cells are non-differentiated
stem cells and/or committed progenitor cells. Additionally the
cells can be, for example, neural cells and oligodendrocyte cells,
skin cells, hepatic cells, muscle cells, bone cells, mesenchymal
cells, pancreatic cells, chondrocytes or stroma cells.
[0229] Further according to this aspect of the present invention
there is provided a pharmaceutical composition for inducing
differentiation in a population of cells. The composition according
to this aspect of the present invention includes a transition metal
chelator of a type and in an amount or concentration effective in
inducing cell differentiation and a pharmaceutically acceptable
carrier.
[0230] According to an embodiment of this aspect of the present
invention the transition metal chelator is a tripeptide, e.g., GGH
and/or GHL. Both are shown in the Examples section hereinunder to
induce differentiation Thus, the transition metal chelator
according to this aspect of the present invention is a peptide or a
peptide analog, or it includes a peptide sequence.
[0231] As used herein in the specification and in the claims
section below the term "peptide" refers to native peptides (either
degradation products or synthetically synthesized peptidis) and
further to peptidomimetics (peptide analogs), such as peptoids and
semipeptoids, which may have, for example, modifications rendering
the peptides more stable while in a body, or more effective in
chelating under physiological conditions. Such modifications
include, but are not limited to, cyclization, N terminus
modification, C terminus modification, peptide bond modification,
including, but not limited to, CH.sub.2--NH, CH.sub.2--S,
CH.sub.2--S.dbd.O, O.dbd.C--NH, CH.sub.2--O, CH.sub.2--CH.sub.2,
S.dbd.C--NH, CH.dbd.CH or CF.dbd.CH, backbone modification and
residue modification. Methods for preparing peptidomimetic
compounds are well known in the art and are specified in
Quantitative Drug Design, C. A. Ramsden Gd., Chapter 17.2, F.
Choplin Pergamon Press (1992), which is incorporated by reference
as if fully set forth herein.
[0232] As used herein the term "amino acid" is understood to
include the 20 naturally occurring amino acids; those amino acids
often modified post-translationally in vivo, including for example
hydroxyproline, phosphoserine and phosphothreonine; and other
unusual amino acids including, but not limited to, 2-aminoadipic
acid, hydroxylysine, isodesmosine, nor-valine, nor-leucine and
omithine. Furthermore, the term "amino acid" includes both D- and
L-amino acids.
[0233] Administration of the differentiation inducing transition
metal chelator can be effected by a pharmaceutical composition
including same, which may further include a pharmaceutically
acceptable carriers, such as thickeners, buffers, diluents, surface
active agents, preservatives, and the like, all as well known in
the art and as is further described above with respect to
differentiation inhibiting chelators.
[0234] Thus, while conceiving and reducing to practice the present
invention it was found that transition metal chelators which bind
copper are either differentiation inducers or inhibitors. It is
believed that differentiation inhibiting chelators are either
binding Copper so efficiently, or cannot enter the cell of present
the cell with copper, so as to reduce Copper availability to the
cell and eventually reduce Copper content in the cell, a result of
which is differentiation arrest and cell expansion, which can be
reversed by Copper addition to the growth medium of the expanding
cells. It is further believed that differentiation inducing
chelators are either binding Copper less efficiently, and can enter
the cell of present the cell with copper, so as to increase Copper
availability to the cell and eventually increase Copper content in
the cell, a result of which is differentiation acceleration and
inhibited proliferation. These assumptions gain strength by the
fact that while chelators inducing differentiation bring about
substantial increase in cellular Copper levels, whereas while
chelators inhibiting differentiation bring about decrease in
cellular Copper levels.
[0235] Based on these findings the present invention offers two
independent or supplementary tests for identifying differentiation
inducing and inhibiting chelators.
[0236] Thus, according to another aspect of the present there is
provided an assay of determining whether a transition metal
chelator which binds copper causes inhibition or induction of
differentiation. The assay according to this aspect of the
invention is effected by culturing a population of stem or
progenitor cells or cells of a substantially non-differentiated
cell line, in the presence of the transition metal chelator and
monitoring differentiation of the cells, wherein if differentiation
is increased as is compared to non-treated cells, the transition
metal chelator induces differentiation, whereas if differentiation
is decreased as compared to non-treated cells, or if
differentiation is absent altogether, the transition metal chelator
inhibits differentiation.
[0237] According to another aspect of the present there is provided
an assay of determining whether a transition metal chelator which
binds copper causes inhibition or induction of differentiation. The
assay according to this aspect of the invention is effected by
culturing a population of cells in the presence of the transition
metal chelator and monitoring copper content of the cells, wherein
if the copper content of the cells is increased as is compared to
non-treated cells, the transition metal chelator induces
differentiation, whereas if the copper content is decreased as
compared to non-treated cells the transition metal chelator
inhibits differentiation.
[0238] Additional objects, advantages, and novel feats of the
present invention will become apparent to one ordinarily skilled in
the art upon examination of the following examples, which are not
intended to be limiting. Additionally, each of the various
embodiments and aspects of the present invention as delineated
hereinabove and as claimed in the claims section below finds
experimental support in the following examples
EXAMPLES
[0239] Reference is now made to the following examples, which
together with the above descriptions, illustrate the invention in a
non limiting fashion.
[0240] Generally, the nomenclature used herein and the laboratory
procedures utilized in the present invention include molecular,
biochemical, microbiological and recombinant DNA techniques Such
techniques are thoroughly explained in the literature. See, for
example, "Molecular Cloning: A laboratory Manual" Sambrook et al.,
(1989); "Current Protocols in Molecular Biology" Volumes I-III
Ausubel, R. M., ed. (1994); Cell Biology: A Laboratory Handbook"
Volumes I-III Cellis, J. E., ed. (1994); "Current Protocols in
Immunology" Volumes I-III Coligan J. E., ed. (1994);
"Oligonucleotide Synthesis" Gait, M. J., ed. (1984); "Nucleic Acid
Hybridization" Hames, B. D., and Higgins S. J., eds. (1985);
"Transcription and Translation" Hames, B. D., and Higgins S. J.,
eds. (1984); "Animal Cell Culture" Freshney, R. I., ed. (1986);
"Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical
Guide to Molecular Cloning" Perbal, B., (1984) and "Methods and
Enzymology" Vol. 1-317 Academic Press; all of which are
incorporated by reference as if fully set forth herein. Other
general references are provided throughout this document. The
procedures therein are believed to be well known in the art and are
provided for the convenience of the reader All the information
contained therein is incorporated herein by reference.
EXAMPLE 1
Imposing Proliferation yet Restricting Differentiation of Stem and
Progenitor Cells by Treating the Cells with Chelators of
Transitional Metals
Experimental Procedures
[0241] CD.sub.34 Cells Selection:
[0242] Peripheral blood "buffy coat" cells derived from a whole
blood unit, peripheral blood cells obtained following
leukapheresis, or cord blood cells were layered on Ficoll-Hypaque
(density 1.077 g/ml) and centrifuged at 1,000.times. g for 20 min.
at room temperature. The interphase layer of mononuclear cells were
collected, washed three times with Ca/Mg free phosphate buffered
saline containing 1% bovine serum albumin (BSA). The cells were
incubated for 30 mm. at 4 .degree. C. with murine monoclonal anti
CD.sub.34 antibody (0.5 .mu.g/10.sup.6 mononuclear cells) and
thereafter isolated using the miniMACS apparatus (Miltenyi-Biotec,
Bergisch, Gladbach, Germany) according to the manufacturer's
protocol.
[0243] Culture Procedures:
[0244] For the expansion of progenitor cells, CD.sub.34.sup.+
enriched fractions or unseparated mononuclear cells were seeded at
about 1-3.times.10.sup.4 cells/ml in either alpha minimal essential
medium containing 10% preselected fetal calf serum (FCS) (both from
GIBCO, Grand Island, N.Y.), or serum-free medium (Progenitor-34
medium, Life Technologies, Grand Island, N.Y.) The media were
supplemented with a mixture of growth factors and transition metal
chelators. The cultures were incubated at 37.degree. C. in an
atmosphere of 5% CO.sub.2 in air with extra humidity. Half of the
medium was changed weekly with fresh medium containing all the
supplements.
[0245] Cloning Potential Evaluations:
[0246] The cloning potential of cells developed in the liquid
culture was assayed, at different intervals, in semi-solid medium.
The cells were washed and seeded in 35 mm dishes in methylcellulose
containing alpha medium supplemented with recombinant growth
factors (SCF, G-CSF, GM-CSF and EPO). Following 2 weeks incubation,
the cultures were scored with an inverted microscope. Colonies were
classified as blast, mixed, erythroid, myeloid, and megakaryocytic,
according to their cellular composition.
[0247] Morphological Assessment:
[0248] In order to characterize the resulting culture populations,
aliquots of cells were deposited on a glass slide (cytocentrifuge,
Shandon, Runcom, UK), fixed and stained in May-Grunwald Giemsa.
Other aliquots were stained by benzidine for intracellular
hemoglobin.
[0249] Immunofluorescence Staining:
[0250] At different intervals, cells from the liquid cultures were
assayed for CD.sub.34 antigen. Aliquots were harvested, washed and
incubated on ice with FITC-labeled anti CD.sub.45 monoclonal
antibody and either PE-labeled anti CD.sub.34 (HPCA-2) monoclonal
antibody or PE-labeled control mouse Ig. After incubation, red
cells were lysed with lysing solution. while the remaining cells
were washed and analyzed by flow cytometer.
[0251] Flow Cytometry:
[0252] Cells were analyzed and sorted using FACStar.sup.plus flow
cytometer (Becton-Dickinson, Immunofluorometry systems, Mountain
View, Calif.). Cells were passed at a rate of 1,000 cells/second
through a 70 mm nozzle, using saline as the sheath fluid A 488 nm
argon laser beam at 250 mW served as the light source for
excitation. Green (FITC-derived) fluorescence was measured using a
530.+-.30 nm band-pass filter and red (PE-derived)
fluorescence--using a 575.+-.26 nm band filter. The PMTs was set at
the appropriate voltage. Logarithmic amplification was applied for
measurements of fluorescence and linear amplification--for forward
light scatter. At least 10.sup.4 cells were analyzed.
Experimental Results
[0253] In an effort to develop culture conditions which stimulate
proliferation and inhibit differentiation of hematopoietic
progenitor cells, CD34.sup.+ cells were cultured with the following
supplements:
[0254] Transition metal chelators such as--tetraethylpentamine
(TEPA), captopril (CAP) penicilamine (PEN) or ether chelators or
ions such as Zinc which interfere with transition metal
metabolism;
[0255] Early-acting cytokines--stem cell factor (SCF), FLT3 ligand
(FL), interleukin-6 (IL-6), thrombopoietin (TPO) and interleukin-3
(IL-3);
[0256] Late-acting cytokines--granulocyte colony stimulating factor
(G-CSF), granulocyte/macrophage colony stimulating factor (GM-CSF)
and erythropoietin (EPO).
[0257] TEPA Effects on Proliferation and Clonability of Short Term
CD.sub.34+ Cultures:
[0258] Addition of TEPA to CD34.sup.+ cells cultured with low doses
of early-acting cytokines resulted in a significant increase in
total cell number, in the number of CD34.sup.+ cells (measured by
flow cytometry utilizing fluorescence labeled specific antibodies,
FIG. 2) and in cell clonability (measured by plating culture
aliquots in semi-solid medium and scoring colonies that develop two
weeks later, FIG. 1), compared to cultures supplemented only with
cytokines. The colonies which developed in semi-solid medium in the
presence of TEPA were of myeloid, erythroid and mixed
phenotype.
[0259] The effects of TEPA were further assessed in cultures
supplemented with either high doses of early cytokines (Table 1) or
with a combination of early- and late-acting cytokines (FIG. 3).
The results indicated that TEPA significantly increased the
clonability and the percentage of CD34.sup.+ cells in these
cultures. As for total cell number it was increased by TEPA in
cultures supplemented with early cytokines (Table 1; FIG. 2),
whereas in cultures supplemented with both early and late
cytokines, TEPA caused a marginal inhibition (FIG. 3).
[0260] Cord blood-derived CD.sub.34 cells were plated in liquid
culture in the presence of: FL--50 ng/ml, SCF--50 ng/ml, IL-6--50
ng/ml, with or without IL-3--20 ng/ml, with or without TEPA--10
.mu.M. On day 7, the percentage of CD.sub.34 cells and the total
cell number were determined. Aliquots equivalent to
1.times.10.sup.3 initiating cells were assayed on days 0 and 7 for
colony forming cells (CFU) by cloning in semi-solid medium CFU
expansion represents the ratio of CFU present on day 7 to CFU
present on day 0
1TABLE 1 The short-term effect of TEPA on CD.sub.34 cells Colonies
CFU Cells/ml CD.sub.34 cells (Per 1 .times. 10.sup.3 expansion TEPA
II-3 (.times. 10.sup.4) (%) initiating cells) (fold) - - 1 1 16 0.3
+ - 2 11.5 140 2.8 - + 5 5 165 3.3 + + 11 20 850 17
[0261] TEPA Effects on Proliferation and Clonability of Long-Term
CD34.sup.+ Cultures:
[0262] Long-term cultures were maintained for 3-5 weeks by weekly
demi-depopulation (one half of the culture volume was removed and
replaced by fresh medium and cytokines). Addition of TEPA resulted
in a higher clonability in long-term cultures supplemented with
either early cytokines (FIG. 4) or both early and late cytokines
(FIG. 3), as compared to cultures supplemented only with
cytokines.
[0263] After three weeks in culture, there was a sharp decrease in
clonability in cultures supplemented only with cytokines, whereas
cultures treated with TEPA in combination with cytokines maintained
high clonability, which was even higher than that of short-term
cultures.
[0264] The Effect of TEPA on the Maturation of Hematopoietic
Cells:
[0265] The effect of TEPA on the maturation of hematopoietic cells
was tested on several models:
[0266] Mouse Erythroleukemic Cells (MEL):
[0267] MEL cells are erythroblast like cells. Following treatment
with several chemicals (differentiation inducers) the cells undergo
erythroid differentiation and accumulate hemoglobin. MEL cells were
cultured in the presence of the differentiation inducer
hexamethylene bisacetamide (HMBA) and the chelators TEPA or
Captopril. At day 3 of the culture, the total number of cells and
the percentage of hemoglobin-containing cells were determined
(Table 2). The results indicated that both TEPA and captopril
inhibited the HMBA-induced differentiation of MEL cells.
[0268] Human Erythroid Cell Cultures
[0269] Normal human erythroid cells were grown according to the
two-phase liquid culture procedure, essentially as described in
references 23-26In the first phase, peripheral blood mononuclear
cells were incubated in the presence of early growth factors for
5-7 days. In the second phase, these factors were replaced by the
erythroid specific proliferation/differentia- tion factor,
erythropoietin.
[0270] The cultures were supplemented with TEPA at the initiation
of the second phase. The total cell number and the percentage of
hemoglobin-containing cells were determined after 14 days. The
results (FIG. 5) showed that in the presence of TEPA there was a
sharp decrease in hemoglobin-containing cells, while the total
number of cells decreased only slightly.
[0271] These results suggest that TEPA inhibits erythroid
differentiation, but does not significantly affect the
proliferation ability of the progenitor cells.
2TABLE 2 The effect of TEPA and captopril on growth and
differentiation of erythroleukemic cells Benzidine Positive
Cells/ml (.times.10.sup.4) Cells (%) Control 31 <1 HMBA 32 46
HMBA + TEPA 5 .mu.M 35 24 HMBA + TEPA 10 .mu.M 35 16 HMBA + TEPA 20
.mu.M 47 16 HMBA + Captopril 20 .mu.M 34 29 HMBA + Captopril 40
.mu.M 34 12
[0272] Murine erythroleukemia cells (MEL), were cultured in liquid
medium supplemented with the differentiation
inducer--hexamethylene-bisacetamide (HMBA, 4 mM), with or without
different concentrations of TEPA or captopril. On day 3, total cell
number and hemoglobin containing (benzidine positive) cells were
determined.
[0273] CD.sub.34+ Initiated Cultures:
[0274] Long term liquid cultures initiated with CD.sub.34+ cells
were maintain with different cocktails of cytokines. Half of the
cultures were continuously supplemented with TEPA. In order to test
the status of cell differentiation, cytospin preparation were
stained with May-Grunwald Giemsa (FIGS. 6a-d). The results showed
that cultures which were maintained for 4-5 weeks without TEPA
contained only fully differentiated cells, while with TEPA the
cultures contained in addition to fully differentiated cells, a
subset of 10% -40% of undifferentiated blast-like cells.
[0275] These results strongly suggest that TEPA induces a delay in
CD34.sup.+ cell differentiation which results in prolonged
proliferation and accumulation of early progenitor cells in
long-term ex-vivo cultures.
[0276] TEPA's Mechanism of Activity:
[0277] In order to determine whether TEPA affects CD34.sup.+ cells
via depletion of tradition metals, such as Copper, two approaches
were taken.
[0278] The first was to assess the effect of different transition
metal chelators: tetra-ethylpentamine (TEPA), captopril (CAP) or
penicilamine (PEN). The results demonstrated that all these
compounds share the same effects on CD34.sup.+ cells as TEPA (FIG.
7).
[0279] The second approach was to supplement TEPA-treated cultures
with Copper. The results indicated that TEPA activities were
reversed by Copper (FIG. 8), while supplementation with other ions,
such as iron and selenium, did not (FIG. 9), at least in the short
to medium term cultures employed herein.
[0280] Zinc, which is known to interfere with transition metal
metabolism, e.g., with Copper metabolism, expand the clonability of
the cultures by itself. This effect was even more pronounced in the
presence of both Zinc and TEPA (FIG. 10).
[0281] In the above examples it is demonstrated that by
supplementing CD.sub.34 cell cultures with early-acting cytokines
and the polyamine agent--tetraethylenepentamine (TEPA), for
example, it is possible to maintain long term cultures (LTC)
without the support of stroma. Three phenomena were evident in
these cultures: (i) continues cell proliferation; (ii) expansion of
clonogenic cells (CFUc); and (iii) maintenance of cells at their
undifferentiated status.
[0282] In contrast, control, TEPA-untreated cultures ceased to
proliferate and to generate CFUc and their cells underwent
differentiation much earlier.
[0283] Thus, TEPA and other transition metal chelators sustains
long-term cultures by inhibiting/delaying cellular differentiation
through chelation of transition metals, Copper in particular.
[0284] The following example further substantiate the results
described hereinabove; teaches optimal culture conditions for
long-term cultures, teaches additional chelating agents that affect
hematopoietic cell differentiation and sheds more light on the
mechanism of activity of TEPA and other chelators on their target
cells.
[0285] CD.sub.34+cells derived from human neonatal cord blood were
purified by immunomagnetic method and then cultured in liquid
medium supplemented with cytokines either with or without
transition metal chelators. At weekly intervals, the cultures were
demi-depopulated by removing half of the culture content
(supernatant and cells) and replacing it with fresh medium,
cytokines and the chelators. At the indicated weeks the cellular
content of the cultures were quantified for total cells (by a
manful microscopic/hemocytometric method), for CD.sub.34.sup.+
cells (by immuno-flow cytometry) and for clonogenic cells (by
cloning the cells in cytokine-supplemented semi-solid medium). The
cultures were initiated with 1.times.10.sup.4 cells, 50-80% of
which were CD.sub.34+and 25-50% of which were CFUc. The results
presented in FIGS. 11 to 24 were calculated per 1.times.10.sup.4
initiating cells (the numbers were multiplied by the dilution
factors).
[0286] FIG. 11 shows the effect of TEPA on long-term CD.sub.34
cultures. Cultures initiated with CD.sub.34 cells in liquid medium
supplemented with early-acting cytokines (in the absence of stromal
cells) could be maintained by TEPA for a long time (>6 weeks).
In such cultures, TEPA supported, in combination with the
cytokines, maintenance and expansion of clonogenic cells (CFUc):
The cultures were started with 2.5.times.10.sup.3 CFUc. Upon
termination after 6 weeks, TEPA-treated cultures contained
300.times.10.sup.3 CFUc, (i.e., a 120-fold expansion) while control
cultures contained no CFUc.
[0287] FIGS. 12-14 show the effect of TEPA on cell proliferation,
CFUc and CFUc frequency in the presence of different combination of
early cytokines. The combination of the early-acting cytokines TPO,
SCF, FLT, IL-6 and TEPA was found to be the optimal combination for
the maintenance and long term expansion of cells with clonogenic
potential.
[0288] FIG. 15 shows the effect of G-CSF and GM-CSF on CFUc
frequency of control and TEPA-supplemented CD.sub.34 cultures.
Supplementing the cultures with the late-acting cytokines G-CSF and
GM-CSF, which stimulate cell differentiation, resulted in rapid
loss of clonogenic cells. This differentiation stimulatory effect
is blocked by TEPA.
[0289] FIGS. 16-17 show the effect of partial or complete
medium+TEPA change on long-term cell proliferation (FIG. 16) and
CFUc production (FIG. 17) The results obtained indicate that for
maintaining maximal expansion, TEPA should be completely replaced,
at least, at weekly intervals.
[0290] FIG. 19 shows the effect of delayed addition of TEPA on CFUc
frequency. It is evident that early exposure of CD.sub.34 cells to
TEPA was crucial for long-term maintenance and expansion of CFUc,
suggesting that TEPA affects differentiation of progenitors at
various stages of differentiation.
[0291] FIG. 20 shows the effect of short-tern preincubation with a
single cytokine on long-term CFUc production. The results indicate
that LTC-CFC are more preserved in TEPA-treated cultures when
supplemented for the first 24 hours with a single cytokine rather
than the full complement of cytokines, suggesting that under the
former conditions cells are blocked more efficiently.
[0292] FIGS. 21a-b show the effect of polyamine chelating agents on
CD.sub.34 cell cultures. Polyamine chelating agents sustained cell
proliferation and expanded CFUc during long term cultures. Among
the compounds tested, the long-chain polyamines, TEPA and PEHA,
were found to be more effective than the short-chain
polyamines.
[0293] FIGS. 22a-b show the effect of transition metal chelating
agents on CD.sub.34 cell cultures. Penicilamine (PEN) and captopril
(CAP), which are known transition metal chelators, sustained cell
proliferation and expansion of clonogenic cells during long-term
cultures.
[0294] FIG. 23a-b show the effect of Zinc on CD.sub.34 cell
cultures. Zinc, which is known to interfere with transition metal
metabolism, Copper in particular, mimicked the effect of the
chelating agents in long term cultures, but to a smaller extent
than the chelators themselves.
[0295] Thus, ex-vivo expansion of hematopoietic progenitor cells is
limited by the progression of these cells into non-dividing
differentiated cells. This differentiation process can be delayed
by cultivating the progenitor cells on stroma cell layer. Since the
stroma supports continuous cell proliferation and long-term
generation of CFUc, it is believed that the stroma inflict an anti
differentiation effect on the progenitor cells.
[0296] According to another embodiment of the present invention
there is provided a method of preservation of stem cells, such as,
but not limited to, cord blood derived stem cells, peripheral blood
derived stem cells and bone marrow-derived stem cells. The method
is effected by handling the stem cell while being harvested,
isolated and/or stored, in a presence of a transition metal
chelator, e.g., TEPA
[0297] Cord blood-derived cells were collected and stored
(unseparated) for 24 hours, at 4.degree. C., either in the presence
or absence of 10 .mu.M TEPA. CD34.sup.+ cells were then separated
using either 10 .mu.M TEPA-PBS buffer or TEPA free PBS buffer,
respectively. Then, cells were grown in long-term cultures in the
presence of 10 .mu.M TEPA.
[0298] The results indicated that cultures which were initiated
with cells that were handled in the presence of TEPA expanded for 8
weeks, whereas cultures initiated from cells stored without TEPA
stopped expanding after 5 weeks only.
[0299] It is well known that it takes usually at least several
hours between cell collection and either freezing or
transplantation.
[0300] These results indicate that addition of a transition metal
chelator, such as TEPA, to the collection bags and the separation
and washing buffers increase the yield of stem cells and improve
their potential for long-term growth, thus facilitate the
short-term take and the long-term repopulation following
transplantation of either "fresh", cryopreserved or ex-vivo
expanded hematopoietic cells.
[0301] Thus, further according to the present invention there are
provided stem cells collection bags and separation and washing
buffers supplemented with an effective amount or concentration of
transition metal chelator, which inhibits differentiation.
[0302] As is specifically demonstrated in the above examples, a
novel system which sustains continuous cell proliferation and
long-term generation of CFUc in stroma-free cultures (FIG. 11) has
been developed. The system combines the use of early-acting
cytokines, such as stem cell factor (SCF), FLT3, interleukin-6
(IL-6), thrombopoietin (TPO) with or without interleukin-3, and
transition metal chelating agents (FIGS. 12-14). The early
cytokines support the survival and proliferation of the progenitors
with reduced stimulus for differentiation compared to late-acting
cytokines, such as G-CSF and GM-CSF (FIG. 15). The chelators
inhibit differentiation through chelation of transition metals,
Copper in particular. Complete medium change at weekly intervals,
as compared to partial change, improved LTC-CFC maintenance,
suggesting that the TEPA-transition metal complex, e.g.,
TEPA-Copper complex, may not be stable (FIGS. 16-17).
[0303] Several lines of evidence suggest that TEPA inhibits
differentiation of early progenitors (FIG. 18) For example, when
TEPA addition was delayed until day 6 of the culture its effects
were reduced as compared to cultures supplemented with TEPA from
day 1 (FIG. 19). While optimal results were obtained when TEPA was
added on day 1, it was advantageous to add the fill complement of
cytokines on day 2. Thus, TEPA-treated cultures which were
supplemented for one day with only one cytokine, e.g., FLT3,
followed by addition of the other cytokines (SCF, TPO and IL-3)
were maintained longer than cultures where all the cytokines were
added at day 1 (FIG. 20). We hypothesize that since cell
differentiation is driven by the cytokines and is dependent on
Copper and other transition metals, inhibition of differentiation
requires depletion thereof prior to exposure to the fill complement
of cytokines. A single cytokine does not support rapid activation
(proliferation and differentiation) but maintains cell viability,
thus allowing TEPA to efficiently chelate transition metals in
quiescent undifferentiated CD.sub.34 cells prior to activation.
[0304] Following screening, various chelating agents have been
found to support continuous cell proliferation and long-term
generation of CFUc and to delay cell differentiation. Among them
are the polyamines such as, but not limited to, TEPA, EDA, PEHA and
TETA (FIGS. 21a-b) or chelators such as, but not limited to,
penicilamine (PEN) and captopril (CAP) (FIGS. 22a-b). Zinc which
interfere with transition metals (Copper in particular) metabolism
also supported LTC-CFC (FIGS. 23a-b).
EXAMPLE 2
The effect of Copper-Chelating Peptides on Proliferation and
Clonability in CD.sub.34 Cell Cultures
Experimental Procedures
[0305] CD.sub.34 Cells Selection:
[0306] Peripheral blood "buffy coat" cells derived from a whole
blood unit, peripheral blood cells obtained following
leukapheresis, or blood cells were layered on Ficoll-Hypaque
(density 1.077 g/ml) and centrifuged at 1,000.times. g for 20
minutes at room temperature. The interphase layer of mononuclear
cells were collected, washed three times with Ca/Mg free phosphate
buffered saline containing 1% bovine serum albumin (BSA). The cells
were incubated for 30 minutes at 4.degree. C. with murine
monoclonal anti CD.sub.34 antibody (0.5 .mu.g/10.sup.6 monoclonal
cells) and thereafter isolated using the miniMACA apparatus
(Miltenyl-Biotec, Bergisch, Gladbach, Germany) according to the
manufacturers protocol.
[0307] Culture Procedures:
[0308] For the expansion of progenitor cells, CD.sub.34.sup.+
enriched fractions were seeded at 1.times.10.sup.4 cells/ml in
alpha minimal essential medium containing 10% preselected fetal
calf serum (FCS) (both from GIBCO, Grand Island, N.Y.). The medium
was supplemented with a mixture of growth factors and Copper
chelators. The cultures were incubated at 37.degree. C. in an
atmosphere of 5% CO.sub.2 in air with extra humidity. Half of the
medium was changed weekly with fresh medium containing all the
supplements.
[0309] The cloning potential of the cultured cells was assayed in
semi-solid 25 medium The cells were washed and seeded in 35 mm
dishes in methylcellulose containing alpha medium supplemented with
30% FCS and further with recombinant growth factors (stem cell
factor (SCF), G-CSF, GM-CSF and erythropoietin (EPO)). Following
two week incubation, the cultures were scored with an inverted
microscope. Colonies were classified as blast, mixed erythroid,
myeloid, and megakaryocytic, according to their cellular
composition.
[0310] Morphological Assessment:
[0311] In order to characterize the resulting culture populations,
aliquots of cells were deposited on a glass slide (cytocentrifuge,
Shandon, Runcorn, UK), fixed and stained in May-Grunwald
Giemsa.
[0312] Immunofluorescence staining for CD.sub.34 antigen:
[0313] Cells were incubated on ice with FITC-labeled anti CD.sub.45
monoclonal antibody and either phycoerythrin (PE)-labeled anti
CD.sub.34 (HPCA-2) monoclonal antibody or PE-labeled control mouse
Immunoglobulins (Ig) After incubation, the cells were washed and
analyzed by flow cytometry.
[0314] Flow Cytometry:
[0315] Cells were analyzed using FACStar.sup.plus flow cytometer
(Becton-Dickinson, Immunofluorometry systems, Mountain View,
Calif.). Cells were passed at a rate of 1,000 cells/second through
a 70 pm nozzle, using saline as the sheath fluid. A 488 nm argon
laser beam at 250 mW served as the light source for excitation.
Green (FITC-derived) fluorescence was measured using a 530.+-.30 nm
band-pass filter and red (PE-derived) fluorescence--using a
575.+-.26 nm band filter. The PMTs was set at the appropriate
voltage. Logarithmic amplification was applied for measurements of
fluorescence and linear amplification--for forward light scatter.
At least 10.sup.4 cells were analyzed.
Experimental Results
[0316] The Effect of Copper-Chelating Peptides on Proliferation and
Clonability in CD.sub.34 Cell Cultures:
[0317] Cultures were initiated with 10.sup.4 cord blood-derived
CD.sub.34.sup.+ cells by plating purified cells in liquid medium in
the presence of SCF, FLT3 and IL-6 (50 ng/ml each) and the
Copper-binding peptides, Gly-Gly-His (GGH) or Gly-His-Lys (GHL) (10
.mu.M each), or the late-acting cytokines G-CSF and GM-CSF (10
ng/ml each). At weekly intervals, the cultures were
demi-depopulated and supplemented with fresh medium, cytokines and
the peptides. After 7 weeks, cells were counted and assayed for
CFUc.
[0318] As shown in FIGS. 25a-b, the results indicated that GGH and
GHL decreased cell number by 10% and 25%, respectively, and
G-CSF+GM-CSF by 20%. The effect on the clonogenic potential of the
cultures was much more pronounced: 80% and 78% decrease by H and
GHL, respectively, and 89% by G-CSF+GM-CSF
EXAMPLE 3
Transition Metal Chelator Assay for Determining the Effect of a
Specific Transition Metals Chelator on Cell Differentiation
Experimental Procedures
[0319] Inhibition of Differentiation:
[0320] MEL (mouse erythroleukemia cell line), 8.times.10.sup.3
cells per ml were incubated for 24 hours with different chelators
at concentrations indicated in Table 3 below. Then, cultures were
supplemented with a differentiation inducer--hexamethylene
bisacetamide, 2 mM. Number of cells and percentage of
differentiated cells (benzidine positive) were determined 72 hours
after addition of the inducer.
[0321] Similarly, HL-60 (human myeloid leukemia cell line),
1.times.10.sup.5 cells per ml were incubated for 24 hours with
different chelators at the concentrations indicated in Table 3
below. Then, cultures were supplemented with the differentiation
inducers--vitamin D or retinoic acid (both at 1.times.10.sup.-7 M).
Number of cells and percentage of differentiated phagocytosing)
cells were determined.
[0322] Induction of Differention:
[0323] HL-60, 1.times.10.sup.5 cells per ml were incubated with
different chelators. Number of cells and percentage of
differentiated (phagocytosing) cells were determined.
[0324] Copper Determination:
[0325] Cells were harvested by centrifugation at 1000.times. g for
5 minutes. The cell pellet was washed three times by re-suspending
the cells in PBS (Ca.sup.++ and Mg.sup.++ free) and centrifugation
at 1000.times. g. An aliquot containing 2.times.10.sup.6 cells was
then transferred into a metal-free Eppendorf tube and the cells
were recovered by centrifugation at 1000.times. g. The cell pellet
was re-suspended in 0.03 M ultra-pure nitric acid to give a
concentration of 1.times.10.sup.7 cells/ml. The cells were
homogenized with a high shear mixer (polytron, Kinematica,
Switzerland) for 1 minutes to disrupt the cell and release
intracellular copper content. Cell samples were vortexed before
transferring to a vial autosampler and analyzed in duplicate by a
Perkin Elmer graphite furnace atomic absorption spectrophotometer
at a wavelength of 324.7 nm. The samples were analyzed against
copper standard solution prepared from a commercial stock solution
that was diluted with 0.03 M ultra pure nitric acid.
Experimental Results
[0326] Table 3 bellow summarized the results for HL-60 cells.
Inhibition of differentiation of MEL cells yielded comparable
results. FIG. 26 provides the 5 chemical structure of the various
chelators employed in these experiments.
3TABLE 3 Positive correlation between the ability of copper
chelators to inhibit or induce differentiation and copper content
in chelator treated cells Compound Copper Differentiation growth
Affinity Inhibition Induction inhibition Average Intracellular ppb
Cu Name (LogK 100 1000 100 1000 100 1000 (% of control)
Concentration tested Cu) nM nM nM nM nM nM 20 .mu.M 100 .mu.M 500
.mu.M Control 49 + - 18 N,N'-bis(3-amino 17.3 - - - - - - 33.8 69
26 2 53 27.9 57 propyl)-1,3- ppb % ppb % ppb % propanediamine
Triethylene tetramine 20.2 + + - - - + 27.7 56 21.2 43 16.8 34 ppb
% ppb % ppb % N,N,Bis(2 aminoethyl) 23.9 + + - - + + 10.8 22 13.4
27 ND 1,3 propane diamine ppb % ppb % Tetraethylene pentamine 24.3
+ + - - - + 31.5 64 24.1 49 17.1 35 (TEPA) ppb % ppb % ppb %
Pentaethylene hexamine + - - - - + 19.3 39 24.5 50 17.2 35 ppb %
ppb % ppb % 1,7-Dioxa-4,10- - - - - - - 35.5 72 36.1 73 35.0 71
diazacyclododecane ppb % ppb % ppb % 1,4,8,11-Tetraaza 15 - - - - -
- 37.9 77 27.4 56 28.3 57 cyclotetradecane-5,7-dione ppb % ppb %
ppb % 1,4,7-Triazacyclononane 15.5 + + - - - - 15.8 32 17.7 36 ND
trihydrochloride ppb % ppb % 1-Oxa-4,7,10- + + - - - - 39.0 79 22.9
46 17.6 36 triazacyclododecane ppb % ppb % ppb % 1,4,8,12-tetraaza
24.4 + + - - + + 13.4 27 12.1 25 9.6 19 cyclopentadecane ppb % ppb
% ppb % 1,4,7,10-Tetraaza 24.8 - - + 27.5 56 73.9 150 cyclododecane
c ppb % ppb % c 1,4,8,11-Tetraaza 27.2 + + - - + + 15 0 30 11.4 23
19.9 40 cyclotetradecane ppb % ppb % ppb % Glycyl-glycyl- - - + + +
+ 202.7 411 582 1278 2592 histidine Cu complex ppb % ppb % ppb %
(GGH-Cu) Glycyl-histidyl-lysine Cu - - + + + + 481 976 473 959 1066
2162 complex (GHK-Cu) ppb % ppb % ppb % ND -- not determined; ppb
-- parts per billion
[0327] As is evident from Table 3 above, good correlation was found
between the ability of chelators to modulate cellular copper
content and their biological activities. Chelators that reduce
cellular copper content are potent differentiation inhibitors. On
the other hand, chelators that increase cellular copper content are
potent differentiation inducers. Indeed, differentiation inhibitory
chelators, such as TEPA, PEHA etc., when tested for their activity
on CD.sub.34+ cells, were found to inhibit differentiation.
Chelators with differentiation inducing activity such as
1,4,7,10-Tetra-azacyclododecane and the copper binding peptides GGH
and HHK were found to stimulate differentiation. Therefore,
screening for the ability of chelators to modulate (increase or
decrease) cellular copper content could be a predictive assay for
the effect of the chelators on various cell types such as the
hematopoietic stem (CD.sub.34+) cells.
EXAMPLE 4
Modulation of Differentiation by Copper Chelators on
Non-Hematopoietic Cells
[0328] As is indicated in the Background section above, and as is
known from the scientific literature, cooper depletion in-vivo
affects a plurality of cell lineages, including, but hematopoietic
cells. It was therefore anticipated that the effect of transition
metal chelators on differentiation is not limited to cells of the
hematpoietic lineage, rather this effect is an underlying
phenomenon shared by all eukaryotic cells.
[0329] Embryonal Stem Cells:
[0330] Embryonal stem cells can be maintained undifferentiated in
culture when the medium is supplemented with Leukemia Inhibitory
Factor (LIF) It was found that TEPA can replace LIF in maintaining
the undifferentiative phenotype of the cells.
[0331] Thus, embryonal stem cells were cultured for 3-4 days
essentially as described in (66), in the presence of LIF (26100
ng/ml) or TEPA (10-20 .mu.M) and their differentiation compared to
non-treated control cells.
4TABLE 4 The effect of TEPA of embryonal stem cells Effect on
Compound added Differentiation Proliferation Control + +/- LIF - +
TEPA - +
[0332] The results presented in Table 4, clearly indicate that TEPA
exerts a similar effect on embryonal stem cells as it does for
other cell types.
[0333] Hepatocytes:
[0334] Livers were dissected from anesthetized BALB/c mice with
sterile tools and immersed into F12 culture medium (Biological
Industries, Kibbutz Bet Ha'Emek, Israel). The livers were washed
three times with 3% BSA/PBS buffer and minced into small pieces
with seizures Following three washes with 3% BSA/PBS the liver
tissue pieces were incubated for 30 minutes with 0.05% collagenase
at 37.degree. C. with continues shaking under 5% CO.sub.2
atmosphere. The digested liver tissue pieces were than mashed by
pressing through a fine mesh strainer. After three washes with 3%
BSA/PBS the liver cells were seeded into F12 culture medium
enriched with: 15 mM HEPES buffer, 0.1 glucose, 10 mM sodium
bicarbonate, 0.5 u/ml insulin, 7.5 ng/ml hydrocortisone and with or
without 15 .mu.g/ml of TEPA and incubated at 37.degree. C. in a 5%
CO.sub.2 atmosphere. After overnight incubation the medium was
removed and the cells were supplemented with fresh enriched F12
medium as described above with or without 15 .mu.g/ml of TEPA.
Hepatocytes were incubated in 35 mm dishes for several weeks with
enriched F12 culture medium with or without 15 .mu.g/ml TEPA at
37.degree. C. under 5% CO.sub.2 atmosphere. Cell culture medium was
replaced every week with a fresh medium. Hepatocytes cultures that
were ex-vivo expanded with TEPA for five weeks contained many
dividing and undifferentiated cells (FIGS. 27a-d), while cultures
that were not treated with TEPA contained a very small amount of
only differentiated cells (FIGS. 27e-f).
[0335] Plant Cells:
[0336] The effect of TEPA on the intracellular copper content of
plant cells was determined as follows. Boston fern Callus tissue
cultures were obtained from a commercial plant tissue culture
production facility (Biological Industries, Kibbutz Bet Ha'Emek,
Israel) and incubated with different concentrations of TEPA in the
culture medium for two days at room temperature. After three washes
with PBS die tissues were suspended in 0.03 M ultra pure nitric
acid and homogenized with a high shear mixer (polytron, Kinematica,
Switzerland) for 3 minutes to disrupt the cells and release
intracellular copper. Cell samples were vortexed before
transferring to a vial autosampler and analyzed in duplicate by a
Perkin Elmer graphite furnace atomic absorption spectrophotometer
at a wavelength of 324.7 nm. The samples were analyzed against
copper standard solution prepared from a commercial stock solution
that was diluted with 0.03 M ultra pure nitric acid.
[0337] Table 5 below summarizes the effect of different TEPA
concentration in the growth medium on the intracellular copper
concentration of plant cells.
5TABLE 5 Effect of different TEPA concentration in the growth
medium on the intracellular copper concentration of plant callus
tissues Average Intracellular TEPA Concentration in Medium Copper
Content (ppb) 0 .mu.M (Control) 36.85 +/- 16.0 10 .mu.M 13.85 +/-
4.09 50 .mu.M 8.45 +/- 0.05 100 .mu.M 7.1 +/- 2.12
[0338] It is evident from Table 5 above that incubation of plant
cells with TEPA causes a reduction of the intracellular content of
copper in the cells.
EXAMPLE 5
Evaluation of the in-vivo Potential of ex-vivo Cultured Cells
Engraftment of SCID Mice by ex-vivo Expanded Human
[0339] Hematopoietic Cells:
[0340] Cord blood purified CD.sub.34+ cells either fresh or
following 2 or 4 weeks of ex-vivo culture (plus or minus TEPA) were
injected into NOD/SCID mice essentially as described in (56). After
4 weeks, the mice were sacrificed and their femora and tibias were
excised and the bone marrow flushed with a syringe fitted with a 25
gauge needle. A single cell suspension was prepared, the cells were
washed and an aliquot counted with Trypan blue.
[0341] In order to quantitate engrafted cells of human origin,
cells were stained with FITC-conjugated anti CD.sub.45 antibodies
and PE-conjugated either anti CD.sub.34, CD.sub.19 or CD.sub.33
antibodies. Anti CD.sub.45 antibodies recognize human, but not
mouse, cells, and thus, indicates the human origin of the
cells.
[0342] The proliferation and differentiation potential of the
engrafted cells was assayed by cloning bone marrow cells in
semi-solid medium under conditions that allow specifically growth
of human derived colonies essentially as described in (56).
[0343] The results (Table 6) indicate that the engraftment
potential of expanded cells is higher than that of fresh cells,
20-60% CD.sub.45+ as compared to 3-6%/CD.sub.45+ cells,
respectively. All 6 cord blood samples that were expanded ex-vivo
in the presence of TEPA succeeded to engraft the animals, whereas
only 2 out of 6 samples that were expanded without TEPA
engrafted.
6 TABLE 6 Ex-vivo .sup.+Engraftment Weeks Treatment CD.sub.45 (%)
CD.sub.34 (%) CD.sub.19 (%) *Colonies CB 2 0 -- 4 1.6 1.7 100 10%
FCS CB 2 2 Cytokines 40 11 15 260 10% FCS CB 2 2 TEPA + 56 13 11
330 10% FCS Cytokines CB 2 0 -- 3 1.2 1.5 70 10% FCS CB 2 2
Cytokines 38 5.7 14 127 10% FCS CB 2 2 TEPA+ 48 13.5 9 528 10% FCS
Cytokines CB 3 0 -- 4 1.8 2.2 250 10% FCS CB 3 2 Cytokines 0 0 0 0
10% FCS CB 3 2 TEPA + 20 4 5 100 10% FCS Cytokines CB 4 2 Cytokines
5 1 0.7 4 1% FCS CB 4 2 TEPA + 28 7 8 185 1% FCS Cytokines CB 4 4
Cytokines 4 2 3 4 1% FCS CB 4 4 TEPA + 40 9 14 267 1% FCS Cytokines
CB 5 4 Cytokines 4.7 1.6 1 5 -FCS CB 5 4 TEPA + 21 6 9 275 -FCS
Cytokines CB 6 2 Cytokines died died died died 10% FCS CB 6 2 TEPA
+ 73 9 26 420 10% FCS Cytokines CB 6 2 Cytokines 6 4 6 8 1% FCS CB
6 2 TEPA + 73 16 19 350 1% FCS Cytokines No. of cells transplanted
per mouse: Fresh CB = 1 .times. 10.sup.5 purified CD.sub.34+ cells;
Ex-vivo expanded = the yield of 1 .times. 10.sup.5 (CB 1-4,6) or
0.5 .times. 10.sup.5 (CB 5) cultured CB CD.sub.34+ cells. *No. of
colonies (erythroid and myeloid) per 2 .times. 10.sup.5 SCID BM
cells. # Human neonatal cord blood. .sup.+Mean of 2-3 mice
[0344] Hematopoietic Reconstitution of Lethally Irradiated
Mice--Fresh vs. Expanded Cells:
[0345] Three month old female Balb/c.times.C57B1/6 F1 mice were
lethally irradiated (1000 rad) and transplanted one day later with
1.times.10.sup.5 fresh bone marrow cells or the yield of
1.times.10.sup.5 bone marrow cells expanded ex-vivo either with or
without TEPA for 3 to 5 weeks, as detailed in Table 7. Peripheral
blood WBC counts were performed on weekly basis.
[0346] The results indicated that WBC recovery was faster in mice
transplanted with bone marrow cells expanded ex-vivo in the
presence of TEPA as compared to fresh or cells expanded without
TEPA.
7 TABLE 7 WBC .times. 10.sup.6/ml Survival Ex-vivo expansion
Ex-vivo expansion with with Ex-vivo In-vivo TEPA + TEPA + (Weeks)
(Days) Fresh BM cytokines cytokines Fresh BM cytokines cytokines
Exp. I 3 13 0.3 0.5 0.7 4/5 4/5 5/5 3 19 0.48 0.58 1.5 4/5 4/5 5/5
Exp. II 3 11 0.17 0.07 0.92 5/5 4/5 5/5 3 29 5.6 0 10.8 5/5 0/5 5/5
Exp. III 5 6 0.1 0.02 0.69 5/5 5/5 5/5 5 11 0.21 0.23 1.27 3/5 5/5
5/5 5 19 n.d. n.d. n.d. 3/5 2/5 4/5 5 27 n.d. n.d. n.d. 3/5 1/5 4/5
No. of cells transplanted per mouse: Fresh BM = 1 .times. 10.sup.5
cells. Ex-vivo expansion = the yield of 1 .times. 10.sup.5 cultured
BM cells. Survival of irradiated mice that were not transplanted
was 0/5 in all three experiments.
[0347] Although the invention has been described in conjunction
with specific embodiments thereof, it is evident that many
alternatives, modifications and variations will be apparent to
those skilled in the art. Accordingly, it is intended to embrace
all such alternatives, modifications and variations that fall
within the spirit and broad scope of the appended claims.
LIST OF REFERENCES CITED
[0348] 1. Van Epps D E, et al. Harvesting, characterization, and
culture of CD.sub.34+ cells from human bone marrow, peripheral
blood, and cord blood. Blood Cells 20:411, 1994.
[0349] 2. Emerson S G. Ex-vivo expansion of hematopoietic
precursors, progenitors, and stem cells: The next generation of
cellular therapeutics. Blood 87:3082, 1996.
[0350] 3. Brugger W, et al. Reconstitution of hematopoiesis after
high-dose chematotherapy by autologus progenitor cells generated
in-vivo. N Engl J Med 333:283, 1995.
[0351] 4. Williams S F, et al. Selection and expansion of
peripheral blood CD.sub.34+ cells in autologous stem cell
transplantation for breast cancer. Blood 87:1687, 1996.
[0352] 5. Zimmerman R M, et al. Large-scale selection of CD.sub.34+
peripheral blood progenitors and expansion of neutrophil precursors
for clinical applications. J Heanatotherapy 5:247, 1996
[0353] 6. Koller M R, Emerson S G, Palsson B O. Large-scale
expansion of human stem and progenitor cells from bone marrow
mononuclear cells in continuous perfusion cultures. Blood 82:378,
1993.
[0354] 7. Lebkowski J S, et al. Rapid isolation and serum-free
expansion of human CD.sub.34+ cells. Blood Cells 20:404, 1994.
[0355] 8. Sandstrom C E, et al. Effects of CD.sub.34+ cell
selection and perfusion on ex-vivo expansion of peripheral blood
mononuclear cells. Blood 86:958, 1995.
[0356] 9. Eiprs P G, et al. Retroviral infection of primitive
hematopoietic cells in continuous perfusion culture. Blood 86:3754,
1995.
[0357] 10. Freedman A R, et al. Generation of T lymphocytes from
bone marrow CD.sub.34+ cells in-vitro. Nature Medicine 2:46,
1996.
[0358] 11. Heslop H E, et al. Long term restoration of immunity
against Epstein-Barr virus infection by adoptive transfer of
gene-modified virus-specific T lymphocytes. Nature Medicine 2:551,
1996.
[0359] 12. Protti M P, et al. Particulate naturally processed
peptides prime a cytotoxic response against human melanoma
in-vitro. Cancer Res 56:1210, 1996.
[0360] 13. Rosenberg S A, et al. Prospective randomized trial of
high-dose interleukin-2 alone or in conjunction with
lymphokine-activated killer cells for the treatment of patients
with advanced cancer. J Natl Cancer Inst 85: 622, 1993.
[0361] 14. Bernhard H, et al. Generation of immunostimulatory
dendritic cells from human CD.sub.34+ hematopoietic progenitor
cells of the bone marrow and peripheral blood Cancer Res 1099,
1995
[0362] 15. Fisch P, et al. Generation of antigen-presenting cells
for soluble protein antigens ex-vivo from peripheral blood
CD.sub.34+ hematopoietic progenitor cells in cancer patients. Eur J
Immunol 26:595, 1996.
[0363] 16. Siena S, et al. Massive ex-vivo generation of functional
dendritic cells from mobilized CD.sub.34+ blood progenitors for
anticancer therapy. Expt Hematol 23:1463, 1996.
[0364] 17. Petzer A L, Zandstra P W, Piret J M, Eaves C J.
Differential cytokine effects on primitive (CD.sub.34+CD38-) human
hematopoietic cells: novel responses to FIT3-ligand and
thrombopoietin. J Exp Med 183:2551, 1996.
[0365] 18. Schwartz R M, et al. In-vitro myelopoiesis stimulated by
rapid medium exchange and supplementation with hematopoietic growth
factors. Blood 78:3155, 1991.
[0366] 19. Verfaillie C M. Can human hematopoietic stem cells be
cultured in-vivo? Stem Cells 12:466, 1994.
[0367] 20. Haylock D N, et al Ex-vivo expansion and maturation of
peripheral blood CD.sub.34+ cells into the myeloid lineage Blood
80:1405, 1992.
[0368] 21. Brugger W, et al. Ex-vivo expansion of enriched
peripheral blood CD.sub.34+ progenitor cells by stem cell factor,
interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and
erythropoietin. Blood 81:2579, 1993.
[0369] 22. Sato N, et al. In-vitro expansion of human peripheral
blood CD.sub.34+ cells. Blood 82:3600, 1993
[0370] 23. Fibach E, Manor D, Oppenheim A, Rachmilewitz E A.
Proliferation and maturation of human erythroid progenitors in
liquid medium. Blood 73:100, 1989.
[0371] 24. Fibach E, Manor D, Treves i, Rachmilewitz E A. Growth of
human normal erythroid progenitors in liquid culture: A comparison
with colony growth in semisolid culture. Internatl J Cell Clon
9:57, 1991.
[0372] 25. Fibach E, Rachmilewitz E A. we two-step liquid
culture--novel procedure for studying maturation of human normal
and pathologic erythroid precursors. Stem Cells 11:36, 1993.
[0373] 26. Dalyot N, Fibach E, Rachmilewitz E, Oppenheim A. Adult
and neonatal patterns of human globin gene expression are
recapitulated in liquid cultures. Exper Hematol 20:1141, 1992.
[0374] 27. Banno S, et al. Anemia and neutropenia in elderly
patients caused by copper deficiency for long-term eternal
nutrition. Rinsho-ketsueki 35:1276, 1994.
[0375] 28. Wasa M, et al. Copper deficiency with pancytopenia
during total parenteral nutrition. JPEN J Parenter Enteral Nutr
18:190, 1994.
[0376] 29. Zidar B L, Shadduck R K, Zeigler Z, Winkelstein A.
Observation on the anemia and neutropenia of human copper
deficiency. Am J Hematol 3:177, 1977.
[0377] 30. Hirase N, et al. Anemia and neutropenia in a case of
copper deficiency: Role of copper in normal hematopoiesis. Acta
Haematol 87:195, 1992.
[0378] 31. Percival S S, Layden-Patrice M. HL-60 cells can be made
copper deficient by incubating with tetraethylenepentamine. J Nutr
122:2424, 1992.
[0379] 32. Percival S S. Neutropenia caused by copper deficiency:
possible mechanisms of action Nutr Rev 53:59, 1995.
[0380] 33. Bae B, Percival S S. Retinoic acid-induced HL-60 cell
differentiation is augmented by copper supplementation. J Nutr
123:997, 1993.
[0381] 34. Bae B, Percival S S. Copper uptake and intracellular
distribution during retinoic acid-induced differentiation of HL-60
cells J Nutr Biochem 5:457, 1994.
[0382] 35. Alter B P. Fetal erythropoiesis in stress hemopoiesis.
Experimental Hematology 7:200, 1979.
[0383] 36. Repair of myelin disease: Strategies and progress in
animal models. Molecular Medicine Today December 1997. pp.
554-561.
[0384] 37. Blau C A et al. Fetal hemoglobin in acute and chronic
stage of erythroid expansion. Blood 81:227, 1993.
[0385] 38. Schechtez A N et al. Sickle cell anemia. In: Molecular
basis of blood diseases. Stamatoyannaopoulos G, Nienhuis A W, Leder
P and Majerus P W Eds. pp. 179-218, Sounders Philadelphia.
[0386] 39. Ross J W and Frant M S. Chelometric indicators,
titration with the solid state cupric ion selective electrode.
Analytical Chemistry 41:1900, 1969.
[0387] 40. Fosmire G J. Zinc toxicity. Am J Clin Nutr 51 (2):
225-227, 1990.
[0388] 41. Simon S R, et al. Copper defilency and siberoblastic
anemia associated with zinc ingestion. Am J Hematol 28(3): 181-183,
1988.
[0389] 42. Hoffman H N 2d, et al. Zinc-induced copper deficiency.
Gastroenterology 94(2): 508-512, 1988.
[0390] 43. Reeves P G, et al. High zinc concentrations in culture
media affect copper uptake and transport in differentiated human
colon adenocarcinoma cells. J Nutr 126(6): 1701-1712, 1996.
[0391] 44. Tashiro Itoh T, et al. Metallothionein expression and
concentrations of copper and zinc are associated with tumor
differentiation in hepatocellular carcinoma. Liver 17(6): 300-306,
1997.
[0392] 45. Cable E E, Isom H C. Exposure of primary rat hepatocytes
in long-term DMSO culture to selected transition metals induces
hepatocyte proliferation and formation of duct-like structures.
Hepatology 26(6): 1444-1457, 1997.
[0393] 46. Kizaki M, et al. Regulation of manganese superoxide
dismutase and other antioxidant genes in normal and leukemic
hematopoietic cells and their relationship to cytotoxicity by tumor
necrosis factor. Blood 82(4): 1142-1150, 1993.
[0394] 47. Brugnera E, et al. Cloning, chromosomal mapping and
charatcerization of the human metal-regulatory transcription factor
MTF-1. Nucleic Acids Res 22(15): 3167-3173, 1994.
[0395] 48. Heuchel R, et al. The transcription factor MTF-1 is
essential for basal and heavy metal-induced metallothionein gene
expression. Embo J 13(12): 2870-2875, 1994.
[0396] 49. Palmiter R D. Regulation of metallothionein genes by
heavy metals appears to be mediated by a zinc-sensitive inhibitor
that interacts with a constitutively active transcription factor,
MTF-1. Proc Natl Acad Sci USA 91(4): 1219-1223, 1994.
[0397] 50. Hatayama T, et al Regulation of hsp70 synthesis induced
by cupric sulfate and zinc sulfate in thermotolerant HeLa cells J
Biochem Tokyo 114(4): 592-597, 1993.
[0398] 51. Filvaroff E, et al. Functional evidence for an
extracellular calcium receptor mechanism triggering tyrosine kinase
activation associated with mouse keratinocyte differentiation. J
Biol Chem 269(34):21735-21740, 1994.
[0399] 52. Okazaki T, et al. Characteristics and partial
purification of a novel cytosolic, magnesium-independent, neutral
sphingomyelinase activated in the early signal genetic modification
of a 1 alpha, 25-dihydroxyvitamin D3-induced HL-60 cell
differentiation. J Biol Chem 269(6): 4070-4077, 1994.]
[0400] 53. Kim H, Lipscomb W N. Differentiation and identification
of the two catalytic metal binding sites in bovine lens leucine
aminopeptidase by x-ray crystallography. Proc Natl Acad Sci USA
90(11): 5006-5010, 1993.
[0401] 54. Fibach, E., Landau, T & Sachs, L. Normal
differentiation of myeloid leukemic cells induced by
differentiation indicing protein. nature 237:276-8, 1972.
[0402] 55. Rosenberg S A, et al. Prospective randomized trial of
high-done IEZ alone or in conduction with lymphokie activated
Kilher cells for the treatment of particular with advanced cancer.
J. Natl. Cancer Inst. 85; 622, 1993.
[0403] 56. Lapidot, T., Pflumio, F., Doedens, M., Murdoch, B.,
Williams. D. E., Dick, J. E. Cytokine stimulation of multilineage
hematopoiesis from immature human cells engrafted in SCID mice.
Science 255:113741, 1992.
Sequence CWU 1
1
2 1 3 PRT Artificial sequence Copper-binding peptide 1 Gly His Lys
1 2 3 PRT Artificial sequence Copper-binding peptide 2 Gly Gly His
1
* * * * *